Drug Delivery Devices
Patent Information
- Application Number
- JP2023533623
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-02
- Filing Date
- 2021-12-01
- Publication Date
- 2024-12-09
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Administering injections poses mental and physical challenges for users and healthcare professionals, and existing drug delivery devices require improvements.
A drug delivery device with a housing element, protective member, and movable member, featuring a telescopic needle shroud and stop features to ensure safe and efficient drug administration, including a spring mechanism for energy transfer and a locking mechanism to prevent re-exposure of the needle.
The device enhances safety and ease of use by ensuring the needle is protected after use, reducing the risk of accidental exposure and improving the user experience.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] A drug delivery device is provided. [Background technology]
[0002] Administering an injection is a process that poses multiple risks and challenges, both mental and physical, for users and medical personnel. Drug delivery devices can aim to make self-injection easier for patients. Conventional drug delivery devices can provide the force to administer the injection by a spring and can use a trigger button or another mechanism to activate the injection. Drug delivery devices can be single-use or reusable devices.
[0003] There is a continuing need for improved drug delivery devices. Summary of the Invention [Problem to be solved by the invention]
[0004] One object to be achieved is to provide an improved drug delivery device. This object is achieved inter alia by the subject matter of claim 1. Advantageous embodiments and further developments are subject to the dependent claims and are presented in the following description and figures. [Means for solving the problem]
[0005] According to at least one embodiment, the drug delivery device includes a housing element. The housing element can be hollow and / or elongated. The housing element can be a sleeve, for example a cylindrical sleeve. In particular, the housing element can be a holder for an energy member, such as a drive spring, i.e. an element in which the energy member can be housed. The energy member can be fixed to the housing element, for example by fixing one end of the drive spring to the housing element.
[0006] According to at least one embodiment, the drug delivery device includes a protective member arranged to be axially movable relative to the housing element and configured to cover the drug delivery element. The protective member can be a needle shroud. For example, the protective member is matingly coupled to the housing element. The protective member can be non-rotatably fixed to the housing element.
[0007] The drug delivery element can be, for example, a needle or a cannula or a catheter. The protective member can be configured such that proximal axial movement of the protective member exposes the drug delivery element and distal axial movement covers the drug delivery element.
[0008] According to at least one embodiment, the drug delivery device includes a movable member movably arranged relative to the housing element. The movable member can be hollow and / or elongated. The movable member can be a sleeve. For example, the movable member is received in the housing element and is circumferentially surrounded by the housing element, e.g., completely surrounded in the circumferential direction.
[0009] In this specification, unless otherwise stated, movement of a member or element or feature is to be understood as movement relative to a housing element.
[0010] According to at least one embodiment, the drug delivery device includes a first stop feature that is axially, and preferably also non-rotatably, fixed to the protective member. The first stop feature can be part of the protective member. For example, the first stop feature is located at or forms the proximal end of the protective member.
[0011] According to at least one embodiment, the drug delivery device includes a second stop feature. The second stop feature is configured to interact with the first stop feature. The two stop features interacting with each other can particularly mean that the two stop features interlock with each other and / or get stuck with each other and / or hit each other. The second stop feature can be part of a movable member or a housing element.
[0012] The housing element and / or the protective member and / or the movable member may comprise or consist of plastic. Each of these may be integrally formed, i.e. formed from a unitary structure or may be integrally formed. The housing element and / or the protective member and / or the movable member may have a main direction of extension along the longitudinal axis of the drug delivery device. The longitudinal axis may run through the center of one or more or all of the above-mentioned elements / members.
[0013] According to at least one embodiment, the drug delivery device is configured to perform a drug delivery operation. The drug delivery operation is a process in which a drug received in the drug delivery device is administered or expelled, in particular via a drug delivery element. The drug delivery operation can take more than 1 or 2 seconds. Additionally or alternatively, the drug delivery operation can take less than 20 seconds or less than 15 seconds. For example, during the drug delivery operation, the drug is administered continuously.
[0014] According to at least one embodiment, the drug delivery device is configured to be switchable from an initial state to a released state, which may also be referred to herein as a locked state or a first locked state or a pre-release state.
[0015] According to at least one embodiment, in the released state, the protective member is in a proximal position. The proximal position may also be referred to herein as a retracted position. The protective member may be configured to expose the drug delivery element in the proximal position. For example, in the proximal position of the protective member, the drug delivery element may be capable of piercing into body tissue.
[0016] According to at least one embodiment, in the released state, a drug delivery operation is performed, e.g., a drug is administered or expelled.
[0017] According to at least one embodiment, in the released state, the movable member moves to a locking position. This means that in the released state, the movable member executes a movement from an initial position (unlocked position) to a locking position. In particular, the locking position is different from the initial position. The initial position is the position of the protection member in the initial state.
[0018] The drug delivery device is particularly configured such that movement of the movable member occurs prior to and / or simultaneously with the drug delivery operation, i.e. simultaneously with drug administration / expulsion, for example the movable member moves continuously during expulsion or administration of the drug.
[0019] According to at least one embodiment, the drug delivery device is configured to be switchable from the released state to the post-release state by moving the protective member distally from the proximal position to the post-release position. The post-release position is a position where the protective member is displaced distally relative to the proximal position. For example, the protective member is moved distally by at least 0.5 cm or at least 1 cm from the proximal position into the post-release position. The distal movement of the protective member can occur automatically, for example driven by a spring, for example a shroud spring. The protective member can be configured to cover the drug delivery element in the post-release position. For example, in the post-release position, the protective member can prevent the drug delivery element from being perforated into body tissue.
[0020] The post-release position may also be referred to herein as an extended position. The post-release state may also be referred to herein as a third locked state.
[0021] According to at least one embodiment, in the post-release state, the protective member is in a post-release position.
[0022] According to at least one embodiment, in the post-release state, the movable member is in a locking position, the movable member being configured such that in the locking position, an interaction of the first and second stop features is enabled such that an attempt to move the protective member in a proximal direction causes the stop features to interact with each other before the protective member reaches the proximal position, the interaction of the stop features then preventing further movement of the protective member in the proximal direction.
[0023] In other words, the drug delivery device is configured such that, in a post-release state, the protective member cannot be returned to the proximal position because the interaction of the first and second stop features locks movement to the proximal position, the interaction of the locking features being enabled by movement of the movable member to the locking position.
[0024] In at least one embodiment, the drug delivery device includes a housing element and a protective member arranged axially movably relative to the housing element and configured to cover the drug delivery element. The drug delivery device further includes a movable member arranged movably relative to the housing element, a first stop feature axially fixed relative to the protective member, and a second stop feature configured to interact with the first stop feature. The drug delivery device is configured to perform a drug delivery operation. Furthermore, the drug delivery device is configured to be switchable from an initial state to a release state, where in the release state, the protective member is in a proximal position and the movable member moves to a locking position. The drug delivery device is configured to be switchable from the release state to a post-release state by moving the protective member from the proximal position to a post-release position in a distal direction. In the post-release state, the protective member is in a post-release position and the movable member is in a locking position, and the interaction of the first and second stop features is enabled, such that an attempt to move the protective member in a proximal direction causes the stop features to interact with each other before the protective member reaches the proximal position. The interaction prevents further movement of the protective member in the proximal direction.
[0025] Such a drug delivery device makes it possible to lock the protective member after use of the drug delivery device so that the drug delivery element, e.g. the needle, is not exposed again, thus increasing the safety of the drug delivery device.
[0026] The drug delivery device as specified herein may be elongated and / or may include a longitudinal axis, i.e., a main axis of extension. A direction parallel to the longitudinal axis is referred to herein as the axial direction. By way of example, the drug delivery device may be cylindrical.
[0027] Further, the drug delivery device may include a longitudinal end, which may be provided to face or press against a skin area of the human body. This end is referred to herein as the distal end. A drug or agent may be delivered through the distal end. The opposite longitudinal end is referred to herein as the proximal end. The proximal end is away from the skin area during use. The axial direction from the proximal end to the distal end is referred to herein as the distal direction. The axial direction from the distal end to the proximal end is referred to herein as the proximal direction. The distal end of a member or element of the drug delivery device is understood herein to be the end of the member / element that is located most distally. Correspondingly, the proximal end of a member or element is understood herein to be the end of the element / member that is located most proximally.
[0028] In other words, "distal" is used herein to designate a direction, end, or surface that is or will be positioned to point or point toward the dosing end of the drug delivery device or a component thereof, and / or that points away from the proximal end, that will be positioned to point away from the proximal end, or that faces away from the proximal end. On the other hand, "proximal" is used herein to designate a direction, end, or surface that is or will be positioned to point or point away from the dosing end and / or the distal end of the drug delivery device or a component thereof. The distal end can be the end closest to the dosing end and / or the end furthest from the proximal end, and the proximal end can be the end furthest from the dosing end. The proximal surface can face away from the distal end and / or face toward the proximal end. The distal surface can face toward the distal end and / or face away from the proximal end. The dispensing end may for example be the end of a needle to which the needle unit is or will be attached to the device.
[0029] As used herein, directions perpendicular to and / or intersecting the longitudinal axis are referred to as radial. Radially inward is a radial direction that points toward the longitudinal axis. Radially outward is a radial direction that points away from the longitudinal axis.
[0030] As used herein, the terms "angular," "azimuthal," or "rotational" are used synonymously. Such directions are perpendicular to the longitudinal axis and perpendicular to the radial direction.
[0031] An element or member or feature being non-rotatably, axially or radially fixed relative to another element or member or feature means that relative movement in the rotational, axial or radial direction between the two elements / members / features is not possible or is prevented.
[0032] In this specification, the terms "protrusion" and "boss" are used synonymously. The term "recess" can particularly refer to a depression or cutout or opening or hole.
[0033] According to at least one embodiment, the drug delivery device is an auto-injector.
[0034] According to at least one embodiment, the movable member is arranged to be movable axially relative to the housing element, i.e. in only one or both axial directions. In particular, the movable member is movable in a proximal direction. For example, in a released state, the movable member moves axially, e.g., proximally, to a locking position. In a released state, the movable member can move at least 0.2 cm or at least 0.5 cm along the longitudinal axis. Additionally or alternatively, in a released state, the movable member can move at most 5 cm or at most 2 cm along the longitudinal axis.
[0035] According to at least one embodiment, the movable member is rotatably arranged relative to the housing element, i.e., movable in only one or both rotational directions relative to the housing element. For example, in a released state, the movable member rotates. The axis of rotation of the movable member can define the longitudinal axis or can coincide with the longitudinal axis.
[0036] According to at least one embodiment, in the released state, the movable member rotates through an angle greater than or equal to any one of the following values: 60°, 80°, 120°, 180°, 270°, 360°. For example, in the released state, the transmission member rotates through at least n times 360°, where n is an integer greater than or equal to 1. For example, n is one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.
[0037] According to at least one embodiment, in an initial state of the drug delivery device, the protective member is in a pre-release position and is distally offset with respect to the proximal position. The distance between the pre-release position and the proximal position along the longitudinal axis can be at least 0.5 cm or at least 1 cm. Additionally or alternatively, this distance can be at most 5 cm or at most 2 cm. The protective member can be configured to cover the drug delivery element in the pre-release position. For example, the protective member is configured to cover the drug delivery element in the pre-release position such that the drug delivery element cannot perforate into the body tissue. The pre-release position can be equal to the post-release position. Alternatively, the post-release position can be distally offset with respect to the pre-release position.
[0038] According to at least one embodiment, in an initial state, the movable member is in an unlocked position, disabling interaction of the first and second stop features, thus allowing the protective member to be moved in a proximal direction from the pre-release position to the proximal position. When moving the protective member from the pre-release position to the proximal position, the first stop feature can be moved across the second stop feature.
[0039] In other words, the drug delivery device is configured such that, initially, the protective member can be moved from the pre-release position to the proximal position without the stop features interacting with each other, which is prevented because the movable member is in the unlocked position.
[0040] According to at least one embodiment, the locking position of the movable member is offset proximally relative to the unlocked position, i.e., in the locking position the movable member is located further proximally than in the unlocked position.
[0041] According to at least one embodiment, the drug delivery device is configured to be switchable from an initial state to a released state by moving the protective member from a pre-release position to a proximal position, In particular, a drug delivery action and / or a movement of the movable member can be triggered by moving the protective member in a proximal direction to a proximal position.
[0042] According to at least one embodiment, the drug delivery device includes a plunger rod. The plunger rod is arranged axially movably relative to the housing element. The plunger rod may be hollow or solid. The plunger rod may be cylindrical, for example hollow cylindrical. The plunger rod may have a main extension direction along a longitudinal axis. If the plunger rod is hollow, it may receive an additional element or member, for example other than an energy member, for driving the plunger rod.
[0043] The plunger rod can be received in the movable member and / or the housing element. For example, the plunger rod is circumferentially surrounded by the movable member and / or the housing element. By way of example, the movable element is a rotating collar surrounding the plunger rod. The plunger rod can include or consist of plastic. For example, the plunger rod is formed as one piece. A main extension direction of the plunger rod can be parallel to the longitudinal axis.
[0044] According to at least one embodiment, the drug delivery device includes an energy member that provides energy for inducing the distal axial movement of the plunger rod. The energy member can be a drive spring, for example a torsion drive spring, particularly a spiral torsion spring or a clock spring or a power spring, or another component configured to induce the movement of the plunger rod, for example a gas cartridge or an electric motor. The drive spring can be made of metal, for example steel. The longitudinal axis can extend through the center of the drive spring.
[0045] According to at least one embodiment, in the released state, the plunger rod is moved in a distal direction by the energy provided by the energy member. For example, in the initial state, the first locking mechanism prevents the plunger rod from being moved in a distal direction by the energy provided by the energy member. When switching to the released state, particularly by moving the protective member to a proximal position, the first locking mechanism can be released, and thus the plunger rod is no longer prevented from being moved in a distal direction by the energy provided by the energy member.
[0046] According to at least one embodiment, in the released state, the movable member is moved by the energy provided by the energy member. This means that the movement of the movable member is induced by the energy member. In particular, the movable member moves simultaneously with the plunger rod. During the movement of the plunger rod, the movable member can move axially and / or rotate.
[0047] According to at least one embodiment, the movable member and the plunger rod are operatively coupled such that movement of the movable member in a first direction is translated into movement of the plunger rod in a distal direction. The first direction can be a rotational direction. For example, in a released state, the energy member induces a force, e.g., a torque, on the movable member, which causes the movable member to move in a first direction, thereby axially moving the plunger rod in a distal direction. The movable member may also be referred to herein as a transmission member.
[0048] According to at least one embodiment, the plunger rod and the movable member are operably coupled via a threaded interface. The threaded interface can be formed directly between the plunger rod and the movable member. The threaded interface can convert the rotational movement of the movable member into the axial movement of the plunger rod. For example, the plunger rod includes a thread that is engaged with a thread of the movable member. The thread of the plunger rod can be an external thread and the thread of the movable member can be an internal thread, or vice versa. The transmission member can be axially fixed to the housing element, for example via an energy member. For example, one end of the drive spring that is not fixed to the housing element is fixed to the transmission member. For example, the transmission member is fixed to the housing such that the force required to move the transmission member in one or both axial directions, particularly in the proximal direction, is greater than the force required to move the plunger rod axially.
[0049] According to at least one embodiment, the plunger rod is non-rotatably fixed to the housing element, for example via a spline interface. This means that the plunger rod does not rotate or is prevented from rotating during its movement along the axial direction. The spline interface can be formed directly between the plunger rod and the housing element. For example, the plunger rod has a spline element and the housing element has a spline element that is complementary to and / or fits into the spline element of the plunger rod. The spline elements of the plunger rod and the housing element can engage with each other, for example with a form lock, thereby preventing rotation of the plunger rod relative to the housing element. One of the spline elements of the housing element and the plunger rod can be a groove and the other of the spline elements of the housing element and the plunger rod can be a protrusion. The protrusion can then engage or protrude into the groove, thereby preventing rotation of the plunger rod. The groove can extend parallel to the longitudinal axis. For example, the groove is formed in the plunger rod and the protrusion is part of the housing element.
[0050] Preferably, the spline interface is close to the threaded interface, for example by a distance of at most 1 cm, or at most 0.5 cm, or at most 0.2 cm, which is beneficial because the torque on the plunger rod is resolved over a short distance, thereby reducing stresses in the plunger rod.
[0051] According to at least one embodiment, in the released state, the second stop feature moves or is moved. This means that the second stop feature is movably arranged relative to the housing element. In particular, the second stop feature can be axially and / or rotatably arranged movably relative to the housing element. In the released state, the second stop feature can move, for example axially and / or rotate, by the energy provided by the energy member. In particular, the second stop feature moves during the drug delivery operation and / or during the movement of the plunger rod.
[0052] According to at least one embodiment, the second stop feature is axially and non-rotatably, preferably also radially, fixed relative to the movable member. In particular, the second stop feature can be part of the movable member.
[0053] The movable member may include a first portion and a second portion disposed one behind the other along a longitudinal axis. The first portion may have a smaller diameter than the second portion. For example, the first portion may be a shaft, e.g., having a cylindrical shape. The second portion may be disk-shaped. The second stop feature may be part of the second portion.
[0054] In particular, the second stop feature can be a distally facing surface of the movable member, e.g. the second part. This surface can extend mainly obliquely or perpendicularly to the longitudinal axis. When interacting with each other, the first stop feature can abut against this surface, thereby preventing further movement of the protective member.
[0055] According to at least one embodiment, the second stop feature extends completely circumferentially around the axis of rotation of the movable member, in particular around the longitudinal axis. The geometry of the second stop feature can be constant over at least 75% or at least 80% of its extension around the axis of rotation / longitudinal axis. In particular, the second stop feature can have rotational or circular symmetry with respect to the axis of rotation / longitudinal axis.
[0056] According to at least one embodiment, in an initial state, the second stop feature is disposed distally relative to the first stop feature, in particular relative to a proximal end of the first stop feature, such that in the initial state, the first stop feature cannot interact with the second stop feature when the protective member is moved in a proximal direction.
[0057] According to at least one embodiment, in the released state, the second stop feature is located proximally relative to the first stop feature, such that movement of the second stop feature, particularly associated with movement of the movable member, activates an interaction between the first and second stop features.
[0058] According to at least one embodiment, the second stop feature is axially, preferably further rotatably and / or radially fixed with respect to the housing element. For example, the second stop feature is part of the housing element. The second stop feature can be an edge of the housing element. The edge can face in a distal direction. The first stop feature can hit the second stop feature when moved in a proximal direction.
[0059] According to at least one embodiment, one of the first and second stop features is a displaceable feature that is radially displaceable. For example, the first stop feature is radially displaceable. The displaceable stop feature can be a flexible arm, in particular an elastic arm. One end of the displaceable stop feature, for example the distal end, can be fixed to a protective member or a housing element or a movable member, and the other end of the displaceable feature, for example the proximal end, can be free and radially displaceable. In other words, the displaceable stop feature can be pivotally connected or integral to a protective member, for example its body, or to a housing element, for example its body, or to a movable member, for example its body. The main extension direction of the displaceable stop feature, in its relaxed state, i.e. in the absence of external forces acting on the displaceable stop feature, can include a component parallel to the proximal direction and a component parallel to the radial direction, for example radially inward. In other words, the displaceable feature in its relaxed state is inclined towards or away from the longitudinal axis.
[0060] According to at least one embodiment, the stop features are configured to pass each other without interaction when the displaceable stop features are in a first radial position and to interact with each other when the displaceable stop features are in a second radial position. The first radial position can be a position displaced radially outwardly relative to the second radial position. In a relaxed state, the displaceable stop features can be in the second radial position.
[0061] For example, when the displaceable stop feature is in a first radial position, the first stop feature and the second stop feature can pass each other without hitting each other. On the other hand, when the displaceable stop feature is in a second radial position, the two stop features can hit each other when the first stop feature approaches the second stop feature during proximal movement of the first stop feature. At the first radial position, the displaceable stop feature can be biased towards the second radial position.
[0062] According to at least one embodiment, the movable member in the unlocked position is configured to hold the displaceable stop feature in a first radial position when the protective member is moved in the proximal direction before the first stop feature reaches the second stop feature. For example, in the unlocked position, a portion of the movable member, e.g. the second portion described above, is located immediately in front of the second stop feature along the proximal direction and holds the displaceable stop feature in the first radial position, so that the first stop feature can pass the second stop feature. In the locking position, the movable member can be arranged not to hold the displaceable stop feature in the first radial position when the first stop feature reaches the second stop feature, so that the displaceable stop feature is transformed to the second radial position before the first stop feature reaches the second stop feature, so that the first stop feature hits the second stop feature.
[0063] According to at least one embodiment, a locking interface, in particular a radial locking interface, is formed between the first and second stop features when the first and second stop features interact with each other, for example the second stop feature includes a recess or notch into which the first stop feature protrudes or engages when the first and second stop features interact with each other.
[0064] According to at least one embodiment, the locking interface is configured to prevent the displaceable stop feature from being displaced to the first radial position. For example, at least one of the first and second stop features includes a beveled surface inclined relative to the longitudinal axis. The beveled surface is a surface against which the first and second stop features abut when the protective member is moved proximally. The beveled surface is preferably configured such that when the first and second stop features abut each other, the displaceable stop feature is moved away from the first radial position, e.g. radially inward. For example, the angle between the beveled surface and the longitudinal axis is at least 10° and at most 80°. The beveled surface can be a surface within a notch.
[0065] According to at least one embodiment, the drug delivery device is configured such that, starting from a released state, during distal movement of the protective member from a proximal position to a post-release position, the displaceable stop feature abuts against the movable member.
[0066] According to at least one embodiment, at least one of the displaceable stop feature and the movable member includes a sliding feature that, when striking the movable member during distal movement, moves the displaceable stop feature radially, so that the displaceable stop feature can pass the movable member. The sliding feature can be a ramp configured to deflect the displaceable stop feature. For example, the sliding feature moves the displaceable stop feature radially outward.
[0067] According to at least one embodiment, in the post-release state, the movable member and / or the second stop feature are prevented from being moved in a proximal direction, e.g., a stop on the housing element prevents proximal movement of the movable member and / or the second stop feature.
[0068] According to at least one embodiment, the housing element is arranged radially between the protective member and the movable member.
[0069] According to at least one embodiment, when interacting with one another, the first stop feature protrudes at least partially into or through a recess or opening in the housing element.
[0070] According to at least one embodiment, in the released state, the movable member moves axially relative to the housing element until it hits an end stop, e.g., a proximal end stop, of the drug delivery device. The end stop can be formed by the housing element or by another element or member axially fixed relative to the housing element. For example, the movable member moves axially, e.g., proximally, by at least 1 mm or at least 5 mm. Preferably, the movable member moves axially and / or rotatably during the axial movement of the plunger rod.
[0071] According to at least one embodiment, in the released state, after hitting the end stop, the movable member continues to rotate, e.g., after hitting the end stop, the movable member continues to rotate at least 360°.
[0072] According to at least one embodiment, in the released state, the movable member moves in a proximal direction, in which case the end stop may be provided in the region of the proximal end of the drug delivery device.
[0073] According to at least one embodiment, the end stop includes a friction reducing element. Additionally or alternatively, the proximal end of the movable member may include a friction reducing element.
[0074] In accordance with at least one embodiment, a low friction interface is formed between the friction reducing elements of the moveable member and the end stop.
[0075] According to at least one embodiment, at least one of the friction-reducing elements is a tapered protrusion. In particular, the protrusion tapers towards the respective other friction-reducing element. The protrusion may have a conical shape. For example, the friction-reducing element of the end stop is a tapered protrusion.
[0076] According to at least one embodiment, the other of the friction-reducing elements is a recess. The friction-reducing element, which is a protrusion, can protrude into the recess when the movable member hits the end stop. The recess can be formed by a concave surface located at the proximal end of the movable member.
[0077] According to at least one embodiment, the recesses and / or protrusions are rotationally symmetric, preferably circularly symmetric, with respect to the axis of rotation and / or the longitudinal axis of the movable member.
[0078] According to at least one embodiment, the energy member is a drive spring, in particular a torsion drive spring, which is connected to the movable member at a first connection point and to the housing element at a second connection point. The connection of the drive spring to the movable member and / or to the housing element is preferably non-releasable or permanent, i.e. the connection cannot be released without breaking this connection or this connection is present in all states of the drug delivery device.
[0079] According to at least one embodiment, during axial movement of the movable member, the first connection point and the second connection point are moved axially relative to each other, in particular, the first connection point is moved proximally relative to the second connection point when the movable member moves proximally, for example in a released state.
[0080] According to at least one embodiment, the drug delivery device includes a housing. The housing element can be fixed to the housing or can be integrated into the housing. The housing is preferably fixed axially and non-rotatably, preferably radially, relative to the housing element. The housing element can be part of the housing, e.g. integrally formed with the housing, or can be a separate element. The housing can comprise or consist of plastic and / or can be integrally formed. The housing can be hollow and / or elongated and / or cylindrical. The housing can be a sleeve. The housing can be configured to hold or receive a drug container, e.g. a syringe. The housing can be configured to hold a drug container such that the drug container is fixed axially and / or non-rotatably and / or radially relative to the housing. The housing element and / or the energy member and / or the plunger rod and / or the movable member can be received in the housing, i.e. circumferentially surrounded by the housing.
[0081] According to at least one embodiment, the drug delivery device includes a medicament container. The medicament container may include a needle. The medicament container may be received in the housing, i.e. may be circumferentially surrounded by the housing. The needle may form a distal end of the medicament container. The medicament container may be located distally with respect to the movable member and / or the plunger rod and / or the energy member, particularly in an initial state. The medicament container may be arranged axially and / or non-rotatably and / or radially fixed with respect to the housing, i.e. it is not moved with respect to the housing during the intended use of the drug delivery device. The medicament container may be a syringe, e.g. a pre-filled syringe. The end of the container opposite the needle may be sealed and closed by a movable member, e.g. a stopper or a piston. The medicament container may contain a drug or agent, e.g. a liquid drug or agent. The drug delivery device may be configured to empty the medicament container when released. In other words, the medicament container may contain an amount of agent sufficient for exactly one drug delivery operation. The drug delivery operation may be performed when the drug delivery device is switched to a release state. The drug delivery device may be a single-use and / or disposable device.
[0082] According to at least one embodiment, the protective member is telescopically coupled to the housing and axially movable relative to the housing. In a post-release state, and preferably also in a pre-release state, the protective member can cover the needle. In a proximal position, the needle can be exposed. In a proximal position, the needle can be pierced into body tissue. In particular, the protective member is a needle shroud.
[0083] According to at least one embodiment, the drug delivery device includes a shroud spring. The shroud spring can be coupled to the protective member and the housing and / or housing element. The shroud spring can be configured to induce a restoring force acting in a distal direction on the protective member when the protective member is in a proximal position and / or when the protective member is moved from a pre-release position toward a proximal position. The drug delivery device can be automatically switched from a released state to a post-release state by the shroud spring moving the protective member from the proximal position to the post-release position.
[0084] According to at least one embodiment, the drug container includes a stopper. The stopper can seal the drug container in a proximal direction. In a released state of the drug delivery device, a distal end of the plunger rod can abut the stopper and can be driven by an energy member to push the stopper in a distal direction. Distal movement of the stopper can result in the drug in the drug container being forced out of the drug delivery device through the needle, also referred to herein as a drug delivery action.
[0085] According to at least one embodiment, in the pre-release state, the plunger rod is axially spaced from the stopper. Thus, in the release state, the plunger rod first moves distally, then strikes the stopper, and then presses the stopper distally. The axial movement of the movable member preferably starts simultaneously with the axial movement of the plunger rod. Alternatively, the axial movement of the transmission member can start only when or after the plunger rod strikes the stopper.
[0086] According to at least one embodiment, the movement of the stopper can commence with a delay compared to the initiation of movement of the movable member and / or plunger rod, for example, the movable member first moves a certain rotational and / or axial distance before the stopper commences movement.
[0087] The drug delivery device can be used as follows: first, the drug delivery device is in its pre-release state; then, the distal end of the drug delivery device is pressed against a skin area of a body, for example, a human body; in this state, the distal end of the protective member can form the distal end of the drug delivery device; this moves the protective member from the pre-release position to the proximal position; this movement biases the shroud spring, which biases the protective member in a distal direction relative to the housing; in the proximal position, the first locking mechanism is released, and the drug delivery device switches from the pre-release state to the released state; in the released state, the drug is delivered, for example injected, into the body tissue; then, the distal end of the drug delivery device can be removed from the skin; the shroud spring moves the release member in a distal direction to a post-release position, thus switching the drug delivery device to a post-release state; in the post-release state, the protective member cannot be returned to the proximal position.
[0088] The drug delivery device described herein will now be described in more detail with reference to the drawings based on exemplary embodiments. In the individual figures, the same reference numerals indicate the same elements. However, the size ratios involved are not necessarily to scale, and the individual elements may be shown with exaggerated size for better understanding. [Brief description of the drawings]
[0089] [Figure 1] 1A-1D are different views of a first exemplary embodiment of a drug delivery device. [Diagram 2] 1A-1D are different views of a first exemplary embodiment of a drug delivery device. [Diagram 3] 1A-1D are different views of a first exemplary embodiment of a drug delivery device. [Figure 4] 1A-1D are different views of a first exemplary embodiment of a drug delivery device. [Diagram 5] 1A-1D are different views of a first exemplary embodiment of a drug delivery device. [Figure 6] 1A-1D are different views of a first exemplary embodiment of a drug delivery device. [Figure 7] 1A-1D illustrate different positions during use of a drug delivery device according to a first exemplary embodiment. [Figure 8] 1A-1D illustrate different positions during use of a drug delivery device according to a first exemplary embodiment. [Figure 9] 1A-1D illustrate different positions during use of a drug delivery device according to a first exemplary embodiment. [Figure 10] 1A-1D illustrate different positions during use of a drug delivery device according to a first exemplary embodiment. [Figure 11] 1A-1D illustrate different positions during use of a drug delivery device according to a first exemplary embodiment. [Figure 12] 1A-1D illustrate different positions during use of a drug delivery device according to a first exemplary embodiment. [Figure 13] FIG. 1 is an exploded view illustrating a drug delivery device according to a first exemplary embodiment. [Figure 14] FIG. 2 shows a subassembly of the drug delivery device according to the first exemplary embodiment in more detail. [Figure 15] FIG. 2 shows a subassembly of the drug delivery device according to the first exemplary embodiment in more detail. [Figure 16] FIG. 2 shows a subassembly of the drug delivery device according to the first exemplary embodiment in more detail. [Figure 17] 2A-2C are different views of a second exemplary embodiment of a drug delivery device. [Figure 18] 2A-2C are different views of a second exemplary embodiment of a drug delivery device. [Figure 19] 2A-2C are different views of a second exemplary embodiment of a drug delivery device. [Figure 20] 2A-2C are different views of a second exemplary embodiment of a drug delivery device. [Figure 21] 2A-2C are different views of a second exemplary embodiment of a drug delivery device. [Figure 22] 2A-2C are different views of a second exemplary embodiment of a drug delivery device. [Figure 23] FIG. 13 is an exploded view showing a subassembly of a drug delivery device according to a second exemplary embodiment. [Figure 24] FIG. 13 is an exploded view showing a subassembly of a drug delivery device according to a second exemplary embodiment. [Diagram 25] 1A-1C show members or arrangements of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate exemplary embodiments of a drive mechanism. [Figure 26] 1A-1C show members or arrangements of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate exemplary embodiments of a drive mechanism. [Figure 27] 1A-1C show members or arrangements of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate exemplary embodiments of a drive mechanism. [Figure 28] 1A-1C show a portion of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate an exemplary embodiment of a first locking mechanism and release of the first locking mechanism. [Figure 29] 1A-1C show a portion of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate an exemplary embodiment of a first locking mechanism and release of the first locking mechanism. [Diagram 30] 1A-1C show a portion of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate an exemplary embodiment of a first locking mechanism and release of the first locking mechanism. [Diagram 31] 1A-1C show a portion of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate an exemplary embodiment of a first locking mechanism and release of the first locking mechanism. [Diagram 32] 1A-1C show a portion of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate an exemplary embodiment of a first locking mechanism and release of the first locking mechanism. [Diagram 33] 1A-1C show a portion of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate an exemplary embodiment of a first locking mechanism and release of the first locking mechanism. [Diagram 34] 1A-1C show a portion of a drug delivery device according to the first and second exemplary embodiments in different positions in use to illustrate a first exemplary embodiment of a third locking mechanism. [Diagram 35] 1A-1C show a portion of a drug delivery device according to the first and second exemplary embodiments in different positions in use to illustrate a first exemplary embodiment of a third locking mechanism. [Diagram 36] 1A-1C show a portion of a drug delivery device according to the first and second exemplary embodiments in different positions in use to illustrate a first exemplary embodiment of a third locking mechanism. [Figure 37] 1A-1C show a portion of a drug delivery device according to the first and second exemplary embodiments in different positions in use to illustrate a first exemplary embodiment of a third locking mechanism. [Figure 38] 1A-1C show a portion of a drug delivery device according to the first and second exemplary embodiments in different positions in use to illustrate a first exemplary embodiment of a third locking mechanism. [Figure 39] 13A-13D show a portion of a drug delivery device in different positions in use to illustrate a second exemplary embodiment of a third locking mechanism. [Diagram 40] 13A-13D show a portion of a drug delivery device in different positions in use to illustrate a second exemplary embodiment of a third locking mechanism. [Diagram 41] 1A-1C show a portion of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate an exemplary embodiment of a fall protection mechanism. [Diagram 42] 1A-1C show a portion of a drug delivery device according to a first and second exemplary embodiment in different positions in use to illustrate an exemplary embodiment of a fall protection mechanism. [Diagram 43] 1A-1D illustrate different subassemblies of a drug delivery device according to a first exemplary embodiment and steps during assembly of the drug delivery device. [Diagram 44] FIG. 2 illustrates a portion of a front sub-assembly of a drug delivery device according to a first exemplary embodiment. [Diagram 45] FIG. 2 illustrates a portion of a front sub-assembly of a drug delivery device according to a first exemplary embodiment. [Figure 46] FIG. 2 illustrates a portion of a front sub-assembly of a drug delivery device according to a first exemplary embodiment. [Figure 47] 1A-1D illustrate different positions in an exemplary embodiment of a method for assembling a drug delivery device according to a first exemplary embodiment. [Figure 48] 1A-1D illustrate different positions in an exemplary embodiment of a method for assembling a drug delivery device according to a first exemplary embodiment. [Figure 49] 2A-2C show separate drive spring holders of drug delivery devices according to first and second exemplary embodiments; [Figure 50] 1A-1D illustrate different positions in an exemplary embodiment of a method for assembling a drug delivery device according to a first exemplary embodiment. [Figure 51] 1A-1D illustrate different positions in an exemplary embodiment of a method for assembling a drug delivery device according to a first exemplary embodiment. [Figure 52] 1A-1D illustrate different positions in an exemplary embodiment of a method for assembling a drug delivery device according to a first exemplary embodiment. [Figure 53] 1A-1D illustrate different positions in an exemplary embodiment of a method for assembling a drug delivery device according to a first exemplary embodiment. [Figure 54] 1A-1D show an exemplary embodiment of a feedback mechanism in different positions. [Figure 55] 1A-1D show an exemplary embodiment of a feedback mechanism in different positions. [Figure 56]1A-1D show an exemplary embodiment of a feedback mechanism in different positions. [Figure 57] 11A-11C show different views of a third exemplary embodiment of a drug delivery device. [Figure 58] 11A-11C show different views of a third exemplary embodiment of a drug delivery device. [Figure 59] 11A-11C show different views of a third exemplary embodiment of a drug delivery device. [Figure 60] 11A-11C show different views of a third exemplary embodiment of a drug delivery device. [Figure 61] 11A-11C show different views of a third exemplary embodiment of a drug delivery device. [Figure 62] 11A-11C show different views of a third exemplary embodiment of a drug delivery device. [Figure 63] FIG. 13 shows a drug delivery device according to a third exemplary embodiment after use. [Figure 64] 13A-13D illustrate different subassemblies of a drug delivery device according to a third exemplary embodiment. [Figure 65] FIG. 13 is an exploded view showing a subassembly of a drug delivery device according to a third exemplary embodiment. [Figure 66] FIG. 13 is an exploded view showing a subassembly of a drug delivery device according to a third exemplary embodiment. [Figure 67] 13A-13D show a portion of a drug delivery device according to a third exemplary embodiment in different positions in use to illustrate the locking mechanism. [Figure 68] 13A-13D show a portion of a drug delivery device according to a third exemplary embodiment in different positions in use to illustrate the locking mechanism. [Figure 69] 13A-13D show a portion of a drug delivery device according to a third exemplary embodiment in different positions in use to illustrate the locking mechanism. [Figure 70] 13A-13D show a portion of a drug delivery device according to a third exemplary embodiment in different positions in use to illustrate the locking mechanism. [Figure 71]11A-11D show different positions during assembly of a drug delivery device according to a third exemplary embodiment. [Figure 72] 11A-11D show different positions during assembly of a drug delivery device according to a third exemplary embodiment. [Figure 73] 11A-11D show different positions during assembly of a drug delivery device according to a third exemplary embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0090] 1. First Exemplary Embodiment of the Drug Delivery Device Figures 1 and 2 show side views of a first exemplary embodiment of a drug delivery device 1000. Figure 1 shows a first view of the drug delivery device 1000 and Figure 2 shows a second view in which the device 1000 is rotated 90° about the longitudinal axis A compared to the first view.
[0091] 1 and 2 also show the coordinate system used herein to specify the location of members or elements or functions. The distal direction D and the proximal direction P run parallel to the longitudinal axis A. The longitudinal axis A is the main axis of extension of the device 1000. The radial direction R is a direction perpendicular to and intersecting the longitudinal axis A. The azimuthal direction C, also called the angular or rotational direction, is a direction perpendicular to the radial direction R and the longitudinal axis A. To increase the clarity of the figures, not all of the following figures show the different directions and axes.
[0092] The drug delivery device 1000 according to the first exemplary embodiment is an auto-injector. The auto-injector 1000 includes a housing 100. At a distal end of the housing 100, a cap 110 is removably attached or coupled to the housing 100. The housing 100 can be integrally formed and can extend from the cap 110 to a proximal end of the auto-injector 1000. The housing 100 is a cylindrical sleeve.
[0093] 1 and 2, the housing 100 includes a window 120 through which a drug container within the housing 100 can be viewed. For example, the fill level of a drug within the drug container or the advancement of a stopper within the drug container, or the clarity of the drug or degradation of the drug can be observed through the window 120.
[0094] Figures 3 and 4 show the auto-injector 1000 in the same manner as Figures 1 and 2, but now the cap 110 and the housing 100 are shown semi-transparently, thus making it possible to see further details of the auto-injector 1000 which are normally completely surrounded and hidden by the housing 100 and the cap 110. It can be seen that the auto-injector 1000 further comprises a transmission member 2 in the form of a rotating collar 2, also called the movable member 2 or the drive member 2, respectively, an energy member 3 in the form of a torsion drive spring 3, in particular a spiral torsion drive spring (also commonly called a clock spring or power spring), and a housing element 4 in the form of a drive spring holder 4.
[0095] The drive spring holder 4 is fixed to the housing 100, such that the drive spring holder 4 cannot be rotated axially or moved radially relative to the housing 100. For example, the drive spring holder 4 is fixed to the housing 100 with the aid of a clip (not shown). Alternatively, the drive spring holder 4 can be part of the housing 100, for example integrally formed therewith. The drive spring holder 4 is received in the housing 100. The housing 100 completely surrounds the drive spring holder 4 in the circumferential direction.
[0096] The torsion drive spring 3 is connected to the drive spring holder 4 at a connection point. At a further connection point, the torsion drive spring 3 is connected to the rotating collar 2. The connection point is not visible in these figures. The rotating collar 2 is arranged axially and rotatably movable relative to the drive spring holder 4. The torsion drive spring 3 circumferentially surrounds a portion of the rotating collar 2. When energized, the torsion drive spring 3 induces a torque on the rotating collar 2. This torque will cause the rotating collar 2 to rotate relative to the drive spring holder 4 if the rotation of the rotating collar 2 is not prevented by a locking mechanism (see further explanation below). The axis of rotation of the rotating collar 2 can define the longitudinal axis A or can be coincident with the longitudinal axis A.
[0097] The auto-injector 1000 further comprises a release member 5 or protective member 5, respectively, in the form of a needle shroud 5, and a drug container holder 6 in the form of a syringe holder 6. The syringe holder 6 may be axially, and preferably non-rotatably, fixed relative to the housing 100. The syringe holder 6 is configured to hold a syringe. The syringe holder 6 includes a window 60 that overlaps / aligns with a window 120 in the housing 100. In this way, the syringe or drug container can be observed through the window 60, 120.
[0098] The needle shroud 5 is arranged to be axially movably relative to the housing 100 or the drive spring holder 4, respectively, and is matingly coupled to the housing 100 or the drive spring holder 4, respectively. In particular, the needle shroud 5 is movable from an extended position, as shown in Figures 3 and 4, in the proximal direction P to a retracted position (see Figures 7 and 8), as will be described in further detail below.
[0099] The needle shroud 5 and the syringe holder 6 are movably coupled to one another via a shroud spring 7. One end of the shroud spring 7 is connected to the syringe holder 6 and the other end of the shroud spring 7 is connected to the needle shroud 5. This coupling is such that movement of the needle shroud 5 in a proximal direction P relative to the syringe holder 6 compresses the shroud spring 7, inducing a force in a distal direction D on the needle shroud 5.
[0100] 5 and 6 show the auto-injector 1000 in two cross-sectional views, again rotated 90° relative to each other about the longitudinal axis. The cut plane includes the longitudinal axis A. In this view, it can be seen that the auto-injector 1000 further includes a plunger rod 1. The plunger rod 1 is disposed mainly within and is circumferentially surrounded by the rotating collar 2. Only a small portion of the plunger rod 1 (less than 50% of its length) protrudes from the rotating collar 2 in the distal direction D. The rotating collar 2 is closed in the proximal direction P, and the plunger rod 1 does not protrude beyond the proximal end of the rotating collar 2. Measured along the longitudinal axis A, the plunger rod 1 is longer than the rotating collar 2.
[0101] The housing 100, housing element 4, plunger rod 1, rotating collar 2, needle shroud 5, syringe holder 6, and cap 110 can all include or consist of plastic. All of these components can each be formed as a single piece. The drive spring 3 and shroud spring 7 can include or consist of a metal, such as steel.
[0102] In Figures 5 and 6 it can be seen that a drug container 8, in this case a syringe 8, is arranged in the syringe holder 6. This syringe 8 can be arranged axially and / or non-rotatably and / or radially fixed with respect to the syringe holder 6 and / or the housing 100. The syringe 8 comprises a cartridge 81 filled with a drug, a needle 80 and a stopper 82. The needle 80 is arranged at the distal end of the syringe 8. The stopper 82 seals the cartridge 81 in a proximal direction P. When the stopper 82 is moved in a distal direction D, the drug contained in the cartridge 81 is forced out of the syringe 8 through the needle 80.
[0103] 5 and 6, it can further be seen that the needle 80 is covered by a needle shield 83, which encloses the needle 80 and projects in a distal direction D beyond the needle 80. The needle shield 83 may be formed from a rubber material. The cap 110 is connected to a gripping portion 111. The gripping portion 111 is held within the cap 110 by one or more bosses. The gripping portion 111 is coupled with the needle shield 83. The gripping portion 111 may be formed from a metal and may include barbs that engage the material of the needle shield 83.
[0104] When the cap 110 is removed from the housing 100, the gripper 111 pulls the needle shield 83 off of the needle 80. The needle 80 is then circumferentially surrounded only by the retractable needle shroud 5.
[0105] 7 and 8 show two cross-sectional views of the auto-injector 1000 in use. A first position in use is shown, in which the cap 110, gripper 111 and needle shield 83 have been removed from the housing 100. The needle shroud 5 protrudes in a distal direction D from the housing 100.
[0106] 7 and 8, the distal end of the auto-injector 1000 formed by the needle shroud 5 can be pressed against a body, e.g., a human body. As a result, the needle shroud 5 moves in a proximal direction P relative to the housing 100 from its extended position. This results in the needle 80 being exposed and protruding beyond the needle shroud 5 in a distal direction D, where it can now pierce or has already pierced body tissue.
[0107] 7 and 8, the auto-injector 1000 is still in a first locked state (as in the previous figures), also referred to as a pre-release or initial state, in which the torsional drive spring 3 is biased and induces a torque on the rotating collar 2. However, a first locking mechanism (also referred to as a first rotational locking mechanism) prevents rotational movement of the rotating collar 2. The first locking mechanism is described in further detail below.
[0108] In the first locked state, the proximal end of the rotating collar 2 is axially spaced from the proximal end stop of the housing 100. This allows axial movement of the rotating collar 2 in the proximal direction P. Furthermore, in the first locked state, the distal end of the plunger rod 1 is axially spaced from the stopper 82 of the syringe 8. Thus, the plunger rod 1 can move axially in the distal direction D a predetermined distance until it hits the stopper 82.
[0109] 9 and 10 show two cross-sectional views of the auto-injector 1000 in a second position during use. The auto-injector 1000 is now in a released state. The needle shroud 5 has been moved further in the proximal direction P to a retracted position. This releases the first locking mechanism and therefore the rotation of the rotating collar 2 is no longer prevented. The torque on the rotating collar 2 induced by the torsion drive spring 3 causes the rotating collar 2 to rotate in a first rotational direction (clockwise or counterclockwise). The drive mechanism translates the rotation of the rotating collar 2 into an axial movement of the plunger rod 1 in the distal direction D. The drive mechanism will be described in further more detail below. After moving a predetermined distance in the distal direction D, the plunger rod 1 can hit the stopper 82 of the syringe 8 and then press the stopper 82 in the distal direction D, so that the drug in the cartridge 81 is forced through the needle 80 and into the tissue.
[0110] As shown in Figures 9 and 10, the rotating collar 2 not only rotates but also moves in a proximal direction P until the proximal end of the rotating collar 2 hits the proximal end stop of the housing 100. The end stop includes a protrusion 101 tapering in a distal direction D. The protrusion 101 can be conical. The proximal end of the rotating collar 2 includes a recess 200. For example, the surface of the proximal end of the rotating collar 2 is in the shape of a concave surface. The protrusion 101 can penetrate into the recess 200 when the proximal end of the rotating collar 2 hits the end stop of the housing 100. The protrusion 101 and the recess 200 can each be designed with rotational or circular symmetry with respect to the rotation axis of the rotating collar 2. In this way, a low-friction interface is formed between the housing 100 and the rotating collar 2, and thus a low-friction rotation of the rotating collar 2 is also enabled when the proximal end of the rotating collar 2 abuts against the housing 100. In particular, the radius at which friction between the rotating collar 2 and the end stop acts approaches or becomes zero and therefore the resulting torque resulting from friction also tends to zero, significantly reducing losses, allowing for reduced spring forces and / or improving injection performance.
[0111] 11 and 12 show two cross-sectional views of the auto-injector 1000 in a third position during use. The torsion drive spring 3 induces a further torque on the rotating collar 2, which, although abutting against the end stop of the housing 100, rotates further, thereby moving the plunger rod 1 further in the distal direction D. The plunger rod 1 presses the stopper 82 further in the distal direction D, so that a predetermined dose of the drug is delivered through the needle 80, e.g., into tissue. Between the described first and third positions, the rotating collar 2, for example, rotates several times about its axis of rotation.
[0112] 11 and 12, the auto-injector 1000 is in a third locked or post-released state in which the needle shroud 5 is again in its extended position, thus circumferentially surrounding the needle 80 such that the needle 80 does not protrude distally beyond the needle shroud 5. Movement of the needle shroud 5 in the extended position occurs automatically due to the force induced by the compressed shroud spring 7 when moving the needle shroud 5 from the extended position towards the retracted position.
[0113] In the third locked state of the auto-injector 1000 shown in Figures 11 and 12, the needle shroud 5 cannot return to the retracted position due to a third locking mechanism, which is described in further detail below.
[0114] 13 shows the auto-injector 1000 of the previous figures in an exploded view. The auto-injector 1000 includes a release subassembly FSA or a front subassembly FSA, respectively, a drive subassembly RSA or a rear subassembly RSA, respectively, and a syringe 8. To assemble the auto-injector 1000, the syringe 8 is inserted into the front subassembly FSA or the rear subassembly RSA, and then the front subassembly FSA is inserted into the rear subassembly RSA. Assembly of the auto-injector 1000 is described in further and more detail below.
[0115] FIG. 14 shows the forward subassembly FSA in a more detailed side view. The syringe holder 6 includes two elongated arms 6b, which extend axially and are spaced apart from each other along an angular direction. The needle shroud 5 also includes two elongated arms 5b, which extend axially and are spaced apart from each other along an angular direction. The needle shroud 5 and the syringe holder 6 are inserted into each other such that the arms 5b of the needle shroud 5 are located between the arms 6b of the syringe holder 6 along an angular direction. It can further be seen that the arms 6b of the syringe holder 6 protrude in the proximal direction P beyond the arms 5b of the needle shroud 5.
[0116] The distal end of the syringe holder 6 is formed by a distal portion 6a in the form of a cylindrical portion 6a. This portion 6a is configured to hold a shroud spring 7. The cylindrical portion 6a is inserted into the shroud spring 7 so that an edge of the syringe holder 6 abuts the proximal end of the shroud spring 7. The shroud spring 7 circumferentially surrounds the cylindrical portion 6a of the syringe holder 6. The shroud spring 7 can be fixed to the cylindrical portion 6a, for example, by adhesive or by mechanical radial interference with the proximal coil of the shroud spring 7.
[0117] FIG. 15 shows the forward subassembly FSA in an exploded view. The forward subassembly FSA includes a cap 110, a gripper 111, a needle shroud 5, a shroud spring 7, and a syringe holder 6. The needle shroud 5 also includes a distal portion 5a in the form of a cylindrical portion 5a that forms the distal end of the needle shroud 5. The cylindrical portion 5a is configured to hold the shroud spring 7. This cylindrical portion 5a is in the shape of a hollow cylinder so that the shroud spring 7 can be inserted into this portion 5a, the distal end of the shroud spring 7 abutting against the bottom area of the cylindrical portion 5a. The shroud spring 7 can be fixed to the cylindrical portion 5a, for example, by adhesive or by mechanical radial interference with the distal coil of the shroud spring 7. In this manner, the needle shroud 5, shroud spring 7, and syringe holder 6 are coupled such that movement of the needle shroud 5 relative to the syringe holder 6 in the proximal direction P compresses the shroud spring 7. The shroud spring 7 may also be held in place by a coupling / snap between the needle shroud 5 and the syringe holder 6 in the most extended position, for example by features 54 and 61, which are described further below.
[0118] 15, the syringe holder 6 includes a support portion 6c disposed proximally relative to the cylindrical portion 6a, and the support portion 6c is disposed between the arms 6b and the cylindrical portion 6a. After the syringe holder 6 is inserted into the needle shroud 5, the arms 5b of the needle shroud 5 cover the support portion 6c, i.e., are disposed radially outward relative to the support portion 6c.
[0119] FIG. 16 shows the rear subassembly RSA in an exploded view. The rear subassembly RSA includes a housing 100, a torsion drive spring 3, a rotating collar 2, a plunger rod 1, and a drive spring holder 4. The drive spring holder 4, the rotating collar 2, and the housing 100 each have the form of a sleeve. When assembling the rear subassembly RSA, the plunger rod 1 is inserted into the rotating collar 2, which is inserted into the torsion drive spring 3 and fixed to the torsion drive spring 3 at one connection point. The torsion drive spring 3 is inserted into the drive spring holder 4 and connected to the drive spring holder 4 at a further connection point. The drive spring holder 4 is inserted into the housing 100.
[0120] 2. Second Exemplary Embodiment of the Drug Delivery Device Figures 17 and 18 show a second exemplary embodiment of a drug delivery device 1000, which in this case is also an auto-injector 1000. Similar to Figures 1 and 2, Figures 17 and 18 show the auto-injector 1000 in two different views rotated 90° relative to each other about the longitudinal axis A.
[0121] 19 and 20 show the auto-injector 1000 of FIGS. 17 and 18 in the same rotated view, but with the housing 100 semi-transparent.
[0122] 21 and 22 show the auto-injector 1000 of FIGS. 17 and 18 in the same rotated view, but now in a cross-sectional view whose intersecting plane includes the longitudinal axis.
[0123] One difference between the auto-injector 1000 according to the second exemplary embodiment and the auto-injector according to the first exemplary embodiment is that in the second exemplary embodiment, the housing 100 includes two members instead of one member. The first member forms the distal member of the housing 100 and the second member forms the proximal member of the housing 100. The two members of the housing 100 are connected to each other, for example with the aid of a clip (not shown). For example, the two members of the housing 100 are fixed to each other such that they do not move axially, rotationally or radially relative to each other.
[0124] FIG. 23 shows in an exploded view the front subassembly FSA of the autoinjector 1000 according to the second exemplary embodiment. The first member of the housing 100 is assigned to the front subassembly FSA. The needle shroud 5 can be inserted into this first member of the housing 100. The shroud spring 7 is connected to the needle shroud 5 and to the first member of the housing 100, so that a proximal movement of the needle shroud 5 relative to the first member of the housing 100 compresses the shroud spring 7. The difference with respect to the first exemplary embodiment is that the autoinjector according to the second exemplary embodiment does not include a syringe holder with two angularly spaced arms. Instead of such a syringe holder, the first member of the housing 100 is configured to hold a drug container, for example in an axially and / or non-rotatably fixed manner. The first member of the housing 100 completely surrounds the needle shroud 5 in the circumferential direction.
[0125] An exploded view of the rear subassembly RSA of the auto-injector 1000 according to the second exemplary embodiment is shown in Fig. 24. This rear subassembly is essentially identical to the rear subassembly RSA of the first exemplary embodiment. Only the second part of the housing 100 is assigned to the rear subassembly RSA, which can be shorter than the housing 100 of the first exemplary embodiment.
[0126] 3. Drive mechanism The conversion of the rotational motion of the rotatable collar 2 induced by the torsion drive spring 3 into axial motion of the plunger rod 1 (drive mechanism) is described in more detail below in conjunction with Figures 25-27.
[0127] Figures 25 and 26 show the components or arrangements of the first and second exemplary embodiment auto-injector 1000 in different positions during use. The components shown include the rear subassembly (only the housing is not shown) and the syringe 8. In Figure 25 the auto-injector 1000 is in a first locked state and in Figure 26 the auto-injector is in a released state.
[0128] As can be seen in Figures 25 and 26, the drive spring holder 4 includes two hollow sections 4a, 4b, both of which may be hollow cylindrical. The two sections 4a, 4b are arranged longitudinally to each other along a longitudinal axis. The first section 4a is arranged more proximally and has a larger inner diameter and a larger outer diameter than the second section 4b.
[0129] The rotating collar 2 is received in the drive spring holder 4. The proximal end of the rotating collar 2 protrudes from the drive spring holder 4 in the proximal direction P. The rotating collar 2 includes an axis 20 and two portions 21, 22 having a diameter larger than the axis 20. The two portions 21, 22 are axially spaced apart from each other and connected via the axis 20. In this exemplary embodiment, the two portions 21, 22 are disk-shaped, but other shapes are also possible. The first portion 21 has a diameter larger than the second portion 22. The first portion 21 is arranged in a first section 4a of the drive spring holder 4, and the second portion 22 is arranged in a second section 4b of the drive spring holder 4. The diameters of the portions 21, 22 are substantially the same as the inner diameters of the assigned sections 4a, 4b, but are small enough to allow rotation of the rotating collar 2 relative to the drive spring holder 4. Furthermore, the diameter of the first portion 21 is larger than the inner diameter of the second section 4b, thereby limiting axial movement of the rotating collar 2 in the distal direction D.
[0130] 25, in the first locked state, the second portion 22 is offset in the proximal direction P from the second bottom ring 4d of the drive spring holder 4. Similarly, the first portion 21 is offset in the proximal direction P from the first bottom ring 4c of the drive spring holder 4.
[0131] The torsion drive spring 3 is received in the first section 4a and is fixed thereto at a connection point. The rotating collar 2 is received in the torsion drive spring 3 such that the torsion drive spring 3 circumferentially surrounds the axis 20 of the rotating collar 2 proximal to the first section 4a. The axis 20 of the rotating collar 2 is connected to the torsion drive spring 3 at a further connection point. The first portion 21 is offset in a distal direction D relative to the torsion drive spring 3. In a first locked state shown in FIG. 25, the torsion drive spring 3 is biased and induces a torque on the rotating collar 2. With the aid of a first locking mechanism, which will be further described below, rotation of the rotating collar 2 is prevented.
[0132] The plunger rod 1 is received in the rotating collar 2. In a first locked state, a portion of the plunger rod 1 protrudes from the rotating collar 2 in a distal direction D. A stopper 82 of the syringe 8 is offset in the distal direction D from the distal end of the plunger rod 1.
[0133] FIG. 26 shows the auto-injector member or arrangement in a released state. The first locking mechanism is released and thus rotation of the rotating collar 2 is no longer prevented. Due to torque induced by the drive spring 3, the rotating collar 2 rotates in a first rotational direction (clockwise or counterclockwise) within the drive spring holder 4. The rotating collar 2 and the plunger rod 1 are operatively coupled via a threaded interface. In this case, the plunger rod 1 includes an external thread 11 and the rotating collar 2 includes an internal thread (not visible) that engages with the external thread 11 of the plunger rod 1. The coupling via the threaded interface is such that rotation of the rotating collar 2 in the first rotational direction is translated into movement of the plunger rod 1 in the distal direction D.
[0134] During the axial movement of the plunger rod 1 induced by the rotation of the rotating collar 2, the plunger rod 1 itself does not rotate. This is realized by the connection between the plunger rod 1 and the drive spring holder 4 via a spline interface. This is further illustrated in FIG. 27, which shows a three-dimensional view of the members / arrangements of the autoinjector. The spline interface is realized by a protrusion 40 of the drive spring holder 4 protruding in a distal direction D from the second bottom ring 4d, which protrusion 40 engages with or protrudes into a groove 10 of the plunger rod 1, respectively. The grooves 10 extend along the longitudinal axis A, i.e. essentially parallel to the longitudinal axis A. The grooves 10 are arranged opposite each other on the plunger rod 1. Instead of two grooves, one groove and one corresponding protrusion 40, as shown in FIG. 27, is also sufficient. However, three or more grooves 10 and associated protrusions 40 can also be used.
[0135] In an exemplary embodiment, the spline interface is close to the thread interface, for example, by a distance of at most 1 cm or at most 0.5 cm. This is beneficial because the torque applied to the plunger rod 1 is resolved over a short distance, thereby reducing stresses in the plunger rod 1. The plunger rod 1 is often a small member that is likely to deform.
[0136] As can be further seen in FIG. 26, the rotating collar 2 not only rotates, as previously described, but also moves axially in the proximal direction P. The movement in the proximal direction P preferably begins as soon as the rotation begins. In this way, the needle shroud 5 can be re-extended if it is removed from the skin too soon. The breakout force of the stopper 82 is typically 5N or more. The ability of the torsion drive spring 3 to resolve the axial load can be less than this.
[0137] In the released state, the plunger rod 1 presses the stopper 82 in the distal direction D until the stopper 82 abuts against a bottom region of the cartridge 81. At this point, further distal movement of the stopper 82 and the plunger rod 1 is prevented. After the movement of the plunger rod 1 and the rotating collar 2 has ended, a portion of the plunger rod 1 remains received in the rotating collar 2.
[0138] An example of the dimensions of the plunger rod 1 is as follows: The plunger rod 1 has a diameter of 8.0 mm and the pitch of the external thread is 3.17 mm. The coefficient of friction is 0.3. The average contact radius, i.e. the position of the thread flank from the central axis of the plunger rod 1, is 3.75 mm.
[0139] An example of a torsion drive spring 3 is as follows. The material is polished and blued SAE 1095 steel. The height of the torsion drive spring is 12.0 mm, the material thickness is 0.168 mm, the length is 840.749 mm, the outer diameter is 20.0 mm, and the arbor diameter is 10.0 mm. The bending stress limit is 2000 N·mm -2 and Young's modulus is 20000N mm -2 and the number of rotations before energization is 3.
[0140] In general, the following conditions for the torsion drive spring have been found to be advantageous: Arbor diameter is between 12 and 25 times the thickness of the material. Length is between 5000 and 15000 times the thickness. Area of the torsion drive spring 3 is half the area of the drive spring holder 4 (e.g. in the first section 4a) ±10%. Bending stress of tempered, polished and blued SAE 1095 steel should not exceed 2000 MPa.
[0141] An example of a syringe 8 used is as follows: The drug in the cartridge 81 has a volume of 2 ml. The viscosity of the material is 50 cP at room temperature. The inner needle diameter is 0.29 mm. The inner cartridge diameter is 8.65 mm. The friction of the stopper 82 is 10 N. The stopper gap, i.e. the initial gap between the proximal end of the stopper 82 and the distal end of the plunger rod 1, is 2 mm.
[0142] 4. First locking mechanism and release of first locking mechanism Each of the aforementioned first locking mechanisms or first rotational locking mechanisms and how they are released are described in further detail below in conjunction with Figures 28-33.
[0143] Fig. 28 shows a cross-sectional view of the auto-injector 1000 of the first and second exemplary embodiments, the cutting plane being perpendicular to the longitudinal axis A and passing through the second part 22 of the rotating collar 2. As can be seen, the drive spring holder 4 comprises a displaceable element 41 in the form of a resilient arm (see also Fig. 27 and Fig. 49). The resilient arm 41 can be integrally formed with the drive spring holder 4 and is arranged in the second section 4b of the drive spring holder 4. The resilient arm 41 is oriented in the circumferential direction, i.e. the main extension direction of the resilient arm 41 is along the angular direction C. One end of the resilient arm 41 is connected to the drive spring holder 4, the other end is free and movable in the radial direction R.
[0144] The resilient arm 41 includes a protrusion 410 that projects radially inward, i.e. toward the longitudinal axis A. The protrusion 410 tapers radially inward. The protrusion 410 includes a beveled surface 410a, which extends essentially parallel to the longitudinal axis A and is inclined with respect to the radial direction R and the angular direction C. For example, the angle α between the beveled surface 410a and the radial direction R is at least 10° and at most 80°, preferably between 30° and 55°.
[0145] 28, the resilient arm 41 is in a first radial position, in which the protrusions 410 engage with or protrude into the recesses 220 of the second portion 22 of the rotatable collar 2, respectively. In this way, a rotation lock interface is formed, connecting the resilient arm 41 and the rotatable collar 2 and preventing the rotatable collar 2 from rotating.
[0146] The first radial position may be the relaxed position of the resilient arm 41 that it would occupy if no further radially inward and outward forces were acting on the resilient arm 41. Alternatively, the resilient arm 41 may be biased towards the first radial position, such that the first radial position is the stressed position of the resilient arm 41.
[0147] As long as the resilient arm 41 is in the first radial position with the projection 410 projecting into the recess 220, the rotation of the rotating collar 2 induced by the torsion drive spring 3 in the first rotation direction is prevented. However, the torque acting on the rotating collar 2 causes the surface of the second portion 22 that defines the recess 220 to be pressed against the inclined surface 410a of the projection 410 of the resilient arm 41. This results in a force tending to move the resilient arm 41 radially outward from the first radial position to the second radial position. In other words, the torque induced by the torsion drive spring 3 biases the resilient arm 41 radially outward. If the radially outward movement were possible, the first locking mechanism would automatically release and the automatic injector 1000 would be in the released state.
[0148] In the first locked state, the arms 5b of the needle shroud 5 are located at the height of the resilient arms 41, i.e. axially overlapping or aligned with the resilient arms 41, preventing the resilient arms 41 from moving radially outwards away from the first radial position. In effect, the resilient arms 41 abut radially outwards against the needle shroud 5, and thus radially outwards movement is prevented. The resilient arms 41 include further projections 411 which project radially outwards and abut against the needle shroud 5. Radial outwards movement of the needle shroud 5 is prevented, for example, by the housing 100 which circumferentially surrounds the needle shroud 5.
[0149] Figure 29 shows a portion of the auto-injector 1000 in the same state as in Figure 28, but now in a cross-sectional view with the longitudinal axis lying in the cutting plane. Here it can be seen that the arm 5b of the needle shroud 5 indeed comprises a first section 50a, i.e. a wall portion, and a second section 50b, i.e. a recess, e.g. a cutout. The recess 50b is offset in the distal direction D relative to the wall portion 50a. In the first locked state, the needle shroud 5 is in its extended position, in which the wall portion 50a blocks the radially outward movement of the resilient arm 41.
[0150] 29 further illustrates that the needle shroud 5 can be moved from its extended position to a retracted position, which should result in axial and rotational overlap or alignment between the recesses 50b and the resilient arms 41. The movement of the needle shroud 5 in the proximal direction P requires a force, also called the actuation force, which includes the force required to compress the shroud spring 7 and the frictional force resulting from the resilient arms 41 pressing against the needle shroud 5.
[0151] As a numerical example, assuming that the torque on the rotating collar 2 induced by the torsion drive spring 3 is 102 Nmm, the radius at which the rotating collar 2 abuts the protrusion 410 is 7.5 mm, and the angle α is 39°, the radial force on the elastic arm 41 should be about 10.57 N. Assuming that the friction coefficient is 0.3, the friction force should be about 3.17 N. Furthermore, assuming that the force for compressing the shroud spring 7 is about 6 N, the starting force should be about 9 N.
[0152] Figures 30 and 31 show parts of the auto-injector 1000 corresponding to those shown in Figures 28 and 29. The needle shroud 5 has now been moved to its retracted position (by overcoming the actuation force). This movement releases the first locking mechanism and thus the auto-injector 1000 is switched from the first locked state to the released state. The recess 50b of the needle shroud 5 is now at the level of the resilient arm 41, so that the radially outward movement of the resilient arm 41 is no longer prevented. The resilient arm 41 is automatically deflected out of its first radial position, induced by the torque on the rotating collar 2, to a second radial position, in which the projection 410 no longer projects into the recess 220, thus disassembling the rotation lock interface and releasing the first locking mechanism. As a result, the rotation of the rotating collar 2 is no longer prevented. The rotating collar 2 begins to rotate due to the force induced by the drive spring 3 (see FIG. 30), thereby causing axial movement of the plunger rod 1 .
[0153] Figures 32 and 33 show portions of the auto-injector 1000 corresponding to those shown in Figures 28 and 29, where the auto-injector 1000 has been switched to a third locked or post-release state, e.g., the distal end of the auto-injector 1000 has been removed from the body, such that the needle shroud 5 automatically moves from the retracted position back to the extended position, induced by the shroud spring 7.
[0154] The projection 411 of the resilient arm 41 includes a sliding feature 411a in the form of a bevel 411a. The bevel 411a and the longitudinal axis may, for example, include an angle between 10° and 80°, inclusive. The edge of the needle shroud 5 that delimits the recess 50b in the proximal direction P may come into contact with this bevel 411a when the needle shroud 5 moves in the distal direction D. When the edge hits the projection 411, the bevel 411a presses the resilient arm 41 radially inwards. In this way, it is possible for the needle shroud 5 to return to the retracted position without getting stuck in the resilient arm 41. A sliding feature may additionally or alternatively be formed in the needle shroud 5 (see Figures 39 and 40).
[0155] If the resilient arms 41 do indeed abut against the edges of the needle shroud 5 when the needle shroud 5 is moved in the distal direction D, the rotating collar 2, in particular the second part 22 of the rotating collar 2, has moved in the proximal direction P, thus allowing the radially inward movement of the resilient arms 41. The second part 22 is now therefore offset in the proximal direction P relative to the resilient arms 41. For this reason, it is particularly beneficial if the rotating collar 2 moves in the proximal direction as soon as the plunger rod 1 starts its distal movement, i.e. before the plunger rod 1 hits the stopper 82. If the user lifts the auto-injector 1000 from the skin early on, for example before the drug starts to be administered, the needle shroud 5 can nevertheless return in the distal direction and can activate the third locking mechanism described below.
[0156] 5.Third locking mechanism / post-release locking mechanism The third locking mechanism or the post-release locking mechanism is described in further detail below in conjunction with Figures 34-40, respectively.
[0157] 34-38 show a first exemplary embodiment of a third locking mechanism. This mechanism is configured to prevent the needle shroud 5 from being moved from the extended position to the retracted position after the drug has been delivered or the auto-injector has been activated once. Thus, the risk of injury from an exposed needle can be reduced. This third locking mechanism can be used in all exemplary embodiments of the auto-injector 1000 described herein.
[0158] Figure 34 again shows a cross-sectional view of a portion of the auto-injector 1000, the cutting plane including the longitudinal axis A. However, compared to the one shown in, for example, Figure 33, the cutting plane has been rotated (see Figure 38 for a perspective view). It can be seen in Figure 34 that the arm 5b of the needle shroud 5 includes a first stop feature 51 in the form of a displaceable element 51 arranged at the proximal end of the arm 5b. The displaceable element 51 is a resilient arm 51 that can be integrally formed with the remainder of the needle shroud 5 and is thus axially and non-rotatably fixed thereto. The resilient arm 51 therefore moves axially when the needle shroud 5 is moved axially.
[0159] As can be seen in FIG. 38, the resilient arm 51 is disposed at the same height as the wall portion 50a when viewed along the longitudinal axis A and is offset in an angular direction C from the wall portion 50a.
[0160] While extending in the proximal direction P, the resilient arms 51 also extend radially inward, i.e. the main extension direction of the resilient arms 51 has a component along the proximal direction P and a component along the radially inward direction. Thus, the proximal end of the resilient arms 51 is located further radially inward than the distal end of the resilient arms 51. The proximal end of the resilient arms 51 is free and radially displaceable. The distal end of the resilient arms 51 is connected to the remaining part of the needle shroud 5. A twist is formed between the distal end of the resilient arms 51 and the remaining part of the needle shroud 5.
[0161] In Fig. 34 the auto-injector 1000 is in a first locked state (also called initial state or pre-release state), in which rotation of the rotating collar 2 is prevented by the first locking mechanism, as described above. The resilient arms 51 are in a first radial position, which is the biased position of the resilient arms 51. The resilient arms 51 are held in the first radial position and are prevented from moving radially inwards by the second part 22 of the rotating collar 2. In this case the drive spring holder 4 comprises a recess or cutout 43 into which the resilient arms 51 protrude. The resilient arms 51 abut radially inwards against the second part 22.
[0162] 35 shows a portion of the auto-injector 1000 in an in-use position, with the needle shroud 5 having been moved from its extended position to its retracted position, thus switching the auto-injector 1000 to a released state. Together with the needle shroud 5, the resilient arms 51 move in the proximal direction P, such that the second part 22 of the rotating collar 2 no longer holds the resilient arms 51 in the first radial position. This allows the resilient arms 51 to move radially inwards to the second radial position. In the released state, with the auto-injector 1000 and the needle shroud 5 in the retracted position, the resilient arms 51 are offset in the proximal direction P relative to the second part 22.
[0163] In the released state of the auto-injector 1000, the rotatable collar 2 moves in a proximal direction P from the unlocked position to the locking position, as shown in FIG.
[0164] FIG. 36 shows a portion of the auto-injector 1000 in a third locked state, also called the post-release state, which is the state after use, i.e. after the drug has been dispensed. The third locked state is the state after the release state. In this third locked state, the required shroud 5 is again in its extended position. As can be seen in FIG. 36, the second part 22 has moved in the proximal direction P to such an extent that the resilient arm 51 is displaced in the distal direction D relative to the second part 22 and the second part 22 is no longer able to hold the resilient arm 51 in the first radial position. Thus, in the third locked state, the resilient arm 51 is in the second radial position. When attempting to move the needle shroud 5 from the extended position towards the retracted position, the resilient arm 51 in the second radial position hits the second stop feature 22a, i.e. the surface of the second part 22 which extends essentially perpendicular to the longitudinal axis and faces in the distal direction D. This prevents further movement of the needle shroud 5 in the proximal direction P. For example, the auto-injector 1000 is configured such that in the third, locked state, when the needle shroud 5 is moved in the proximal direction P before the needle is exposed, the resilient arm 51 abuts against the surface 22a of the second part 22.
[0165] When the resilient arm 51 strikes the surface 22a of the second part 22, a locking interface is formed between the resilient arm 51 and the surface 22a. For this purpose, a recess 221 or notch 221 is formed in the surface 22a, which engages the proximal end of the resilient arm 51 when the resilient arm 51 strikes the surface 22a. The recess 221 is delimited by a slope 221a that is inclined with respect to the longitudinal axis A and the radial direction. For example, the angle between the slope 221a and the longitudinal axis and / or the radial direction is between 10° and 80°, inclusive. When the proximal end of the resilient arm 51 engages the recess 221, the resilient arm 51 strikes the slope 221a, slides along the slope 221a, and is thereby moved radially inward. The recess 221 with the slope 221a thus prevents the resilient arm 51 from sliding radially outward along the surface 22a.
[0166] The surface 22a of the second portion 22 may extend circumferentially around the longitudinal axis and / or axis of rotation of the rotatable collar 2 by at least 270° and may have a constant geometric form along its extension in the angular direction. In this way, the function of the third locking mechanism is approximately independent as to how far the rotatable collar 2 rotates in the released state.
[0167] As can be further seen in Figs. 34-36, the resilient arm 51 includes a sliding feature 51a in the form of a ramp 51a. During the movement of the needle shroud 5 from the retracted position to the extended position, the ramp 51a hits the proximal edge of the second part 22. The ramp 51a is designed to slide the resilient arm 51 along the edge of the second part 22, thus pushing the resilient arm 51 radially outward. This allows the resilient arm 51 to pass the second part 22 without getting stuck by the second part 22. After passing the second part 22 while moving towards the extended position, the resilient arm 51 bounces back to the second radial position.
[0168] 37 shows in cross-section the auto-injector 1000 in the third, locked state. As can be seen, the needle shroud 5 cannot be moved in the proximal direction P far enough to expose the needle 80 because first the resilient arm 51 hits the surface 22a of the second part 22.
[0169] Figures 39 and 40 show a second exemplary embodiment of the third locking mechanism, which can also be used in all exemplary embodiments of the auto-injector described herein.
[0170] The main difference with respect to the first exemplary embodiment is that in the third, locked state of the auto-injector 1000, when moving the needle shroud 5 towards the retracted position, the resilient arm 51 hits against a stop feature 40a axially fixed to the drive spring holder 4, rather than against a stop feature axially fixed to the rotating collar 2. The stop feature 40a is formed by an edge of the drive spring holder 4. The edge 40a defines a recess / cutout in the drive spring holder 4 in the proximal direction P.
[0171] A flap 46 is axially fixed to the drive spring holder 4 and can for example be formed integrally therewith, and partially fills this recess. The distal end of the flap 46 is connected to the drive spring holder 4, and the proximal end of the flap 46 is free and radially displaceable. The proximal end of the flap 46 is spaced from the edge 40a by a small gap.
[0172] In the first locked state, when the needle shroud 5 is still in the extended position, the rotating collar 2, in particular the second part 22 of the rotating collar 2, abuts radially outwardly against the flap 46 of the drive spring holder 4 and holds the flap 46 in a first radial position, in which the flap 46 ends radially outwardly substantially flush with the edge 40a. The second part 22 prevents the flap 46 from being displaced radially inward. On the other hand, the flap 46 abuts against the elastic arm 51 of the needle shroud 5. In the first radial position of the flap 46, the flap 46 holds the elastic arm 51 in its first radial position.
[0173] Because the flap 46 ends flush with the edge 40a and is held in its first radial position by the second portion 22, the next movement of the needle shroud 5 in the proximal direction P allows the resilient arms 51 to pass the edge 40a without getting stuck thereon. Further movement of the needle shroud 5 to its retracted position releases the first locking mechanism, switching the auto-injector 1000 from the first locked state to the released state and moving the rotatable collar 2 together with the second portion 22 in the proximal direction P to the locked position. The needle shroud 5 is shown in its retracted position in FIG. 39.
[0174] By moving the needle shroud 5 again from its retracted position to its extended position, the resilient arms 51 pass the edge 40a and come to rest at the level of the flap 46. This position is shown in figure 40. The auto-injector 1000 is now in a third locked state. The resilient arms 51, and possibly the flap 46, can be biased radially inwards. Thus, the resilient arms 51 and the flap 46 move radially inwards and each reach a second radial position. This is possible because the elements are no longer held in their respective first radial positions by the second part 22 of the rotating collar 2.
[0175] The second radial position of the flap 46 causes it to not end up flush with the edge 40a of the drive spring holder 4. Thus, when the needle shroud 5 is moved from the extended position towards the retracted position, the resilient arm 51 abuts the edge 40a, thereby preventing further movement of the needle shroud 5 in the proximal direction P.
[0176] 6.Fall protection mechanism An exemplary embodiment of the drop protection mechanism is described in further detail below in relation to Figures 41 and 42. The drop protection mechanism prevents the first locking mechanism from being released when the auto-injector 1000 is unintentionally dropped. In fact, when the auto-injector 1000 of the exemplary embodiment described herein is in the first locked state, movement of the rotating collar 2 in the proximal direction P should release the first locking mechanism.
[0177] 41 shows a portion of the auto-injector 1000 of the first and second exemplary embodiments in a cross-sectional view showing the first member of the fall protection mechanism. In the first locked state of the auto-injector 1000, when the needle shroud 5 is still in the extended position (initial position), the second part 22 and the resilient arm 41 engage with each other (the protrusion 410 projects into the recess 220), and this engagement is maintained by the needle shroud 5 holding the resilient arm 41 in its radial position as described in connection with the first locking mechanism. However, this engagement also establishes an axial locking interface, thereby preventing axial movement of the rotating collar 2 at least in the proximal direction P.
[0178] For this purpose, the projection 410 of the elastic arm 41 is a stepped projection and has two sections 410b, 410c (see also FIG. 49). The recess 220 in the second part 22 of the rotating collar 2 is a stepped recess and also has two sections 220b, 220c. The sections 410b, 410c are connected by a surface 410d extending essentially perpendicular to the longitudinal axis. The sections 220b, 220c are also connected by a surface 220d extending essentially perpendicular to the longitudinal axis. The surface 220d is arranged distal to the surface 410d. These surfaces 220d, 410d abut or hit each other when the rotating collar 2 is moved in the proximal direction P, in this way the rotating collar 2 is prevented from moving in the proximal direction P as long as the projection 410 protrudes into the recess 220.
[0179] However, the first part of the fall protection mechanism described in connection with FIG 41 may also be released if the needle shroud 5 is unintentionally moved in the proximal direction P. Thus, in one exemplary embodiment, the fall protection mechanism includes a second part shown in connection with FIG 42.
[0180] 42 shows a portion of the auto-injector in cross-section, the cutting plane extending parallel to the longitudinal axis A. The distal end of the auto-injector is shown, with the cap 110 still connected to the housing 100. The cap 110 is in its most proximal position and cannot be moved further in the proximal direction P relative to the housing 100, since it would hit the housing 100 if moved in this direction. The cap 110 comprises a radially displaceable cap locking element 110a, i.e. a resilient arm 110a, which with its projection 110b protruding radially inwards engages with a cap locking element 52, i.e. a recess 52, in particular a cutout 52, in the needle shroud 5.
[0181] In Fig. 42 the auto-injector 1000 is shown when it is dropped resulting in a proximal movement of the needle shroud 5. Due to its proximal movement the needle shroud 5, in particular the edge of the needle shroud 5 that delimits the recess 52 in the distal direction D, hits the projection 110b. This prevents further movement of the needle shroud 5 in the proximal direction P as long as the cap 110 is connected to the housing 100. Therefore, the needle shroud 5 cannot reach a retracted position where it would no longer hold the resilient arms 41 in their radial position.
[0182] In the position shown in FIG. 42, the housing 100 circumferentially surrounds the resilient arm 110a and abuts or nearly abuts the resilient arm 110a, thereby preventing radially outward movement of the resilient arm 110a, such that the resilient arm 110a cannot move radially outward or can only move slightly radially outward.
[0183] The protrusion 110b is located at the proximal end of the resilient arm 110a of the cap 110. Usually, when the drug delivery device is not dropped, the edge of the needle shroud 5 that defines the recess 52 in the distal direction D is located further distal than that shown in FIG. 42. When removing the cap 110, the cap 110 is moved in the distal direction D until the protrusion 110b hits said edge of the recess 52. Then, in this position of the cap 110, the housing 100 does not prevent the resilient arm 110a from being moved radially outward, so that the resilient arm 110a can move radially outward. The resilient arm 110a can be disengaged from the recess 52 and the cap 110 can be completely removed. The protrusion 110b has a slope (sliding function) that hits the edge of the recess 52 when the cap 110 is moved in the distal direction D, thereby deflecting the resilient arm 110a radially outward.
[0184] 7. Subassembly, Assembly, and Second Locking Mechanism Figure 43 shows in exploded view the front subassembly FSA (also called release subassembly FSA or receptacle holder subassembly FSA) and the rear subassembly RSA (also called drive subassembly RSA) of the autoinjector according to the first exemplary embodiment, as well as the position of the front subassembly FSA and the rear subassembly RSA when assembled into the autoinjector 1000. These figures correspond to Figures 13, 15 and 16. Reference is therefore primarily made to the description relating to these figures.
[0185] What can be seen in Fig. 43 is that the support portion 6c of the syringe holder 6 includes first rotation locking features 61 in the form of protrusions 61 or ribs 61 that project radially outwardly and have a primary direction of extension along the longitudinal axis. These ribs 61 are configured to engage with recesses 54 in the arms 5b of the needle shroud 5, in particular second rotation locking features 54 in the form of slots 54. The recesses 54 are also elongated, have a primary direction of extension along the longitudinal axis and are longer than the ribs 61, so that when engaged, relative axial movement between the needle shroud 5 and the syringe holder 6 is possible.
[0186] FIG. 44 shows the forward subassembly FSA in a perspective view. As mentioned above, the needle shroud 5 includes two arms 5b, which are located between the two arms 6b of the syringe holder 6 along the angular direction. The arms 6b of the syringe holder 6 protrude in the proximal direction P beyond the arms 5b of the needle shroud 5. The needle shroud 5 and the syringe holder 6 are connected by the shroud spring 7 and the rotation locking features 61, 54, so that the needle shroud 5 can be moved axially but not rotationally relative to the syringe holder 6.
[0187] In Figure 45, a portion of the front subassembly FSA of Figure 44 is shown. A window 60 is formed in arm 6b of syringe holder 6, through which a syringe or drug container placed in syringe holder 6 can be viewed. Window 60 is bounded by wall portion 60a of syringe holder 6. The diameter of window 60 decreases radially inwards.
[0188] The syringe holder 6 further includes radially outwardly projecting snap features 62, or ribs. Respective snap features 62 are disposed at distal and proximal ends of the window 60. The snap features 62 are configured to engage the housing 100 to secure the syringe holder 6 thereto, thus preventing axial and rotational movement of the syringe holder 6 relative to the housing 100.
[0189] 45 , rib 61 protrudes into recess 54, thereby allowing axial movement of needle shroud 5 relative to syringe holder 6, but preventing rotational movement of needle shroud 5 relative to syringe holder 6. To that end, the width of recess 54 may be substantially the same as the width of rib 61.
[0190] 46 shows a detailed view of the distal end of the forward subassembly FSA, with the cap 110 attached to the needle shroud 5. The protrusions 110b of the resilient arms 110a protrude into the recesses 52 of the needle shroud 5, so that the cap 110 is loosely held in place against the needle shroud 5.
[0191] Figure 47 shows a portion of the rear subassembly RSA in a perspective view. Figure 48 shows the rear subassembly RSA in a cross-sectional view, with the longitudinal axis A extending in the cutting plane. Figure 50 shows the rear subassembly RSA in a cross-sectional view, with the cutting plane extending perpendicular to the longitudinal axis A. An exemplary embodiment of the second locking mechanism is shown based on these figures.
[0192] As can be seen in FIG. 47, a recess 44, in particular a cutout, is formed in the first section 4a of the syringe holder 4. The first part 21 of the rotating collar 2 includes a displaceable axial locking element 210 in the form of a resilient arm 210 or clip 210. The resilient arm 210 is radially displaceable. The resilient arm 210 is configured to protrude into the recess 44 when in the first radial position. In this case, the rear subassembly RSA is in a second locked state. Due to the engagement of the resilient arm 210 and the recess 44, when the rotating collar 2 is moved in the proximal direction P, the resilient arm 210 hits an edge of the drive spring holder 4 that defines the recess 44 in the proximal direction P, thus establishing an axial locking interface and preventing proximal movement of the rotating collar 2 relative to the drive spring holder 4. This is one part of the second locking mechanism, also called the axial locking mechanism.
[0193] 48, in the second locked state, the second portion 22 of the rotating collar 2 abuts against the second bottom ring 4d of the drive spring holder 4. The first portion 21 of the rotating collar 2 abuts against the first bottom ring 4c of the drive spring holder 4.
[0194] The second locking mechanism also comprises a protrusion 45 (see also FIG. 49) which is part of the second part 4b of the drive spring holder 4 projecting radially inwards. The protrusion 45 cannot move in any direction relative to the remainder of the drive spring holder 4. The protrusion 45 can have the same form as the first section 410b of the protrusion 410 of the resilient arm 41. The protrusion 45 is offset in the distal direction D relative to the resilient arm 41 or the protrusion 410, respectively. Furthermore, the second locking mechanism comprises the second section 22 of the rotating collar 2, in which the aforementioned recess 220 also forms part of the aforementioned first locking mechanism.
[0195] In the second locked state, the projection 45 projects into the recess 220 (see FIG. 50), thereby establishing a rotation locking interface. This engagement prevents rotation of the rotating collar 2 (the biased torsion drive spring 3 may already be in a state where it induces a torque on the rotating collar 2 in the second locked state). This is another member of the second locking mechanism, also referred to as the second rotation locking mechanism.
[0196] The second rotational locking mechanism does not require the needle shroud 5 to maintain the second locked state because the protrusions 45 are not radially displaceable. Thus, unless the rotating collar 2 is moved in the proximal direction P, rotation of the rotating collar 2 is not possible.
[0197] Figure 51 shows the auto-injector in an assembled position, with the rear and front subassemblies of the previous figures nested together, and Figure 52 shows the same assembled position as Figure 51 in cross section.
[0198] As can be seen in Fig. 52, the arms 6b of the syringe holder 6 each include or form at their proximal end a pushing element 63 and a release element 64. The release element 64 protrudes in the proximal direction P beyond the pushing element 63. Furthermore, the pushing element 63 is offset radially inwards with respect to the release element 64. When mated together, the release element 64 first hits the resilient arm 210, moving the resilient arm 210 radially inwards, thus releasing the axial locking mechanism. This is achieved by the fact that the resilient arm 210 has a slope inclined with respect to the longitudinal axis, and a force acting on the slope in the proximal direction P presses the resilient arm 210 radially inwards.
[0199] Simultaneously or after mating of the rear subassembly with the front subassembly, the pressing element 63 comes against the first section 21 of the rotating collar 2 and presses the rotating collar 2 in the proximal direction P (see also FIG. 53). This releases the second rotation locking mechanism and transfers it from the second locked state to the first locked state. With the pressing of the rotating collar 2 in the proximal direction P, the needle shroud 5 is moved into a position that holds the resilient arms 41 in their first radial position, so that the first locked state is occupied. As a result of pressing the rotating collar 2 in the proximal direction P during assembly, the recess 220 in the second part 22 disengages the projection 45 and then engages the projection 410 of the resilient arms 41 (see also FIG. 49).
[0200] 8.Feedback mechanism 54-56 show exemplary embodiments of feedback mechanisms. Such feedback mechanisms may be used in any of the exemplary embodiments of the drug delivery devices described herein.
[0201] Figure 54 shows a portion of an exemplary embodiment of a drug delivery device / auto-injector 1000 having such a feedback mechanism. In Figure 54, the auto-injector 1000 can be in a first locked state (initial state).
[0202] The feedback mechanism comprises a plunger rod 1 received in a rotating collar 2. The rotating collar 2 can be designed as explained in connection with the previous figures. In particular, the rotating collar 2 is a sleeve. The plunger rod 1 is hollow, for example hollow cylindrical. A feedback energy member 14 in the form of a spring 14, for example a compression spring, is received in the plunger rod 1, i.e. in its cavity. Furthermore, a feedback element 12 in the form of a piston 12 is received in the plunger rod 1. The spring 14 is connected to the piston 12 and to the plunger rod 1 and is compressed. The spring 14 induces a force in the proximal direction P on the piston 12, i.e. the piston 12 is biased in the proximal direction P relative to the plunger rod 1.
[0203] The plunger rod 1 includes axially oriented displaceable arms 13. The displaceable arms 13 may be elastic arms 13 and are arranged at the proximal end of the plunger rod 1. The displaceable arms 13 each include a stop feature 130 in the form of a protrusion 130 at the respective proximal end. Each of the displaceable arms 13, together with its protrusion 130, is radially displaceable. Each of the displaceable arms 13 is in a first radial position. The displaceable arms 13 may be biased radially outward. However, the displaceable arms 13 are held in the first radial position by the side walls of the rotating collar 2 circumferentially surrounding the plunger rod 1 at least at the height of the displaceable arms 13.
[0204] A projection 130 of the displaceable arm 13 projects into the cavity of the plunger rod 1. The proximal end of the piston 12 abuts the projection 130. This prevents the piston 12 from being driven by the spring 14 to move in the proximal direction P beyond the projection 130.
[0205] As can be seen in Fig. 54, the piston 12 and the projection 130 each include a sliding feature in the form of a ramp inclined relative to the longitudinal axis and the radial direction. The piston 12 and the projection 130 abut each other at the ramp, thereby biasing the projection 130 or the displaceable arm 13, respectively, radially outward.
[0206] 55 shows the auto-injector 1000 in a released state. The torsional drive spring induces a torque on the rotating collar 2, which begins to rotate in a first rotational direction, thereby moving the plunger rod 1 in a distal direction D. The biased spring 14 and piston 12 move with the plunger rod 1 in the distal direction D. During this movement, the displaceable arm 13 of the plunger rod 1 is held in a first radial position by the side wall of the rotating collar 2 still circumferentially surrounding the resilient arm 13.
[0207] In the region of the distal end of the rotating collar 2, i.e. in the region between the first section 21 and the second section 22, the side wall of the rotating collar 2 is interrupted by a recess 23. When the plunger rod 1 reaches the feedback position, the displaceable arm 13 or the projection 130, respectively, overlaps this recess 23 axially and non-rotatably. The displaceable arm 13 is therefore no longer held in the first radial position. Being biased radially outwards, the displaceable arm 13 leaves the first radial position and moves radially outwards to a second radial position. In the second radial position, the piston 12 is no longer prevented from moving in the proximal direction P relative to the plunger rod 1, driven by the spring 14, past the projection 130. This is shown in FIG. 56.
[0208] 56, it can be seen that the piston 12 moves in the proximal direction P due to the force induced by the spring 14, thereby leaving the plunger rod 1 and eventually striking the proximal end 201 of the rotating collar 2 forming the impact feature 201. This strike can trigger an audible and / or tactile feedback indicating to the user the end of the drug delivery process. For example, the auto-injector is designed such that the strike of the piston 12 against the impact feature 201 produces a noise of at least 20 dB.
[0209] 9. Third Exemplary Embodiment of the Drug Delivery Device Figures 57 and 58 show a third exemplary embodiment of a drug delivery device 1000. Figure 57 is a side view and Figure 58 is a side view rotated 90° about the longitudinal axis A relative to Figure 57. The drug delivery device 1000 is an auto-injector.
[0210] The auto-injector 1000 includes a housing 100 having a window 120. The window 120 can be used to inspect the fill level of a drug container or syringe or the progression of a stopper within the housing 100 or drug clarity or drug degradation.
[0211] The auto-injector 1000 further includes a protective member 5 in the form of a needle shroud 5 that is matingly coupled to the housing 100 and is axially movable relative to the housing 100 .
[0212] 59 and 60 show the auto-injector 1000 of FIGS. 57 and 58 in the same view, but now the housing 100 is shown semi-transparently, making it possible to see further members and elements of the auto-injector 1000. It can be seen that the auto-injector 1000 further comprises a rear cap 102 closing the housing 100 at the proximal end. Furthermore, the auto-injector 1000 comprises a drive spring holder 4, which is hollow, for example a sleeve. In the drive spring holder 4, a torsion drive spring 3 is received. The torsion drive spring can be a spiral torsion spring. In the torsion drive spring 3 and the drive spring holder 4, a rotation collar 2 is received. Furthermore, a movable member 9, also called an actuation element 9, is provided in the form of an actuation collar 9. The actuation collar 9 is releasably axially connected to the needle shroud 5, such that an axial movement of the needle shroud 5 induces an axial movement of the actuation collar 9. An actuation collar 9 is disposed downstream of the torsion drive spring 3 in the distal direction D and circumferentially surrounds a portion of the rotation collar 2 .
[0213] Additionally, the auto-injector 1000 includes a shroud spring 7 that couples the needle shroud 5 to the housing 100. The connection via the shroud spring 7 is such that proximal movement of the needle shroud 5 relative to the housing 100 compresses the shroud spring 7. This compression biases the needle shroud 5 in a distal direction D relative to the housing 100.
[0214] Figures 61 and 62 show the auto-injector 1000 of Figures 57 and 58 in the same view, but now in a cross-sectional view in which the cutting plane includes the longitudinal axis A. In this view, it can be seen that the auto-injector 1000 further comprises a plunger rod 1. The plunger rod 1 is mainly received in and circumferentially surrounded by the rotating collar 2. Only a small portion of the plunger rod 1 (less than 50% of its length) protrudes from the rotating collar 2 in the distal direction D. The rotating collar 2 is closed in the proximal direction P, and the plunger rod 1 does not protrude beyond the proximal end of the rotating collar 2. Measured along the longitudinal axis, the plunger rod 1 is longer than the rotating collar 2.
[0215] The housing 100, housing element 4, plunger rod 1, rotating collar 2, needle shroud 5, and actuation element 9 can all include or consist of plastic. All of these components can each be formed integrally. The drive spring 3 and shroud spring 7 can include or consist of a metal, such as steel.
[0216] In Fig. 61 and Fig. 62 it can be seen that a drug container 8, in this case a syringe 8, is arranged in a housing 100. This syringe 8 can be arranged axially and / or non-rotatably and / or radially fixed with respect to the housing 100. The syringe 8 comprises a cartridge 81 filled with a drug, a needle 80 and a stopper 82. The needle 80 is arranged at the distal end of the syringe 8. The stopper 82 seals the cartridge 81 in a proximal direction P. When the stopper 82 is moved in a distal direction D, the drug contained in the cartridge 81 is forced out of the syringe 8 through the needle 80.
[0217] 61 and 62, it can further be seen that the needle 80 is covered by a needle shield 83, which encloses the needle 80 and protrudes beyond the needle 80 in a distal direction D. The needle shield 83 can be removed prior to using the auto-injector 1000.
[0218] To use the auto-injector 1000, the distal end of the auto-injector 1000 formed by the needle shroud 5 can be pressed against a body, e.g., a human body, such that the needle shroud 5 moves from its extended position in a proximal direction P relative to the housing 100. This exposes the needle 80, which protrudes in a distal direction D and can now pierce body tissue.
[0219] 61 and 62, the auto-injector 1000 is still in an initial state, hereinafter referred to as the locked state, in which the torsional drive spring 3 is biased and induces a torque on the rotating collar 2. However, a locking mechanism prevents rotational movement of the rotating collar 2. The locking mechanism is described in further detail below.
[0220] In this locked state, the proximal end of the rotating collar 2 can be axially spaced from the proximal end stop of the housing 100. This allows axial movement of the rotating collar 2 in the proximal direction P. Furthermore, in the locked state, the distal end of the plunger rod 1 is axially spaced from the stopper 82 of the syringe 8. Thus, the plunger rod 1 can move axially in the distal direction D a predetermined distance until it hits the stopper 82.
[0221] The needle shroud 5 can be moved in the proximal direction P to a retracted position. This releases the locking mechanism and thus the rotation of the rotating collar 2 is no longer prevented. The automatic injector switches from the locked state to the released state. The torque on the rotating collar 2 induced by the torsion drive spring 3 causes the rotating collar 2 to rotate in a first rotational direction (clockwise or counterclockwise). For example, the rotating collar 2 rotates several times around its rotation axis. A drive mechanism, for example the drive mechanism described above, converts the rotation of the rotating collar 2 into an axial movement of the plunger rod 1 in the distal direction D. After moving a predetermined distance in the distal direction D, the plunger rod 1 can hit the stopper 82 of the syringe 8 and then press the stopper 82 in the distal direction D, so that the drug in the cartridge 81 is forced through the needle 80 and into the tissue.
[0222] The rotating collar 2 can not only rotate but also move in the proximal direction P until the proximal end of the rotating collar 2 hits the proximal end stop of the housing 100. The end stop includes a protrusion 101 tapering in the distal direction D. The protrusion 101 can be conical. The proximal end of the rotating collar 2 includes a recess 200. For example, the surface of the proximal end of the rotating collar 2 is in the shape of a concave surface. The protrusion 101 can penetrate into the recess 200 when the proximal end of the rotating collar 2 hits the end stop of the housing 100. The protrusion 101 and the recess 200 can each be designed with rotational or circular symmetry with respect to the rotation axis of the rotating collar 2. In this way, a low-friction interface is formed between the housing 100 and the rotating collar 2, and thus a low-friction rotation of the rotating collar 2 is also enabled when the proximal end of the rotating collar 2 abuts against the housing 100. In particular, the radius at which friction between the rotating collar 2 and the end stop acts approaches or becomes zero and therefore the resulting torque resulting from friction also tends to zero, significantly reducing losses, allowing for reduced spring forces and / or enhancing injection performance.
[0223] 63 shows in cross-section the automatic injector 1000 according to the third exemplary embodiment after use. The plunger rod 1 hits the stopper 82 and presses it in the distal direction D. As a result, the drug in the cartridge 81 is forced out of the syringe 8 through the needle 80, e.g., whereby the drug is injected into body tissue.
[0224] 64 shows different subassemblies of an automatic injector 1000 according to a third exemplary embodiment. The automatic injector 1000 includes a forward subassembly FSA. The forward subassembly FSA includes a housing 100, a needle shroud 5, and a shroud spring 7 connecting the housing 100 and the needle shroud 5.
[0225] The auto-injector 1000 further includes a rear sub-assembly RSA having a plunger rod 1 , a rotation collar 2 , a torsion drive spring 3 , a drive spring holder 4 , and an activation collar 9 .
[0226] When assembling the front subassembly FSA and the rear subassembly RSA, the syringe 8 is first fitted into the housing 100 of the front subassembly FSA, and then the rear subassembly RSA is fitted into the housing 100. Finally, the rear cap 102 is attached to the proximal end of the housing 100 and can be fixed to the housing 100 via a clip.
[0227] 65 shows the forward subassembly FSA in an exploded view. The needle shroud 5 includes a hollow cylindrical distal portion 5a into which the shroud spring 7 can be fitted. Furthermore, the needle shroud 5 includes two arms 5b extending in the proximal direction P from the cylindrical portion 5a.
[0228] FIG. 66 shows the rear subassembly RSA in an exploded view.
[0229] 9.1 Drive mechanism of the drug delivery device according to the third exemplary embodiment The drive mechanism of the automatic injector according to the third exemplary embodiment can be designed as the drive mechanism described above.
[0230] 9.2 Locking mechanism of the drug delivery device according to the third exemplary embodiment FIG. 67 shows a portion of an automatic injector 1000 according to a third exemplary embodiment in a locked state.
[0231] The upper part of Fig. 67 above the horizontal dashed line shows a portion of the auto-injector 1000 in side view. The lower part of Fig. 67 below the dashed line shows a portion of the auto-injector in a side view rotated 90° about the longitudinal axis A relative to the upper part.
[0232] FIG. 70, for example, shows the auto-injector 1000 in a cross-sectional view, also in a locked state, with the intersecting plane perpendicular to the longitudinal axis A.
[0233] Considering first Fig. 67, the needle shroud 5 includes a coupling feature 53 in the form of a resilient arm 53 having a protrusion that projects radially inwards. The actuation collar 9 has a coupling feature 92 in the form of a recess 92 or opening 92. The protrusion of the resilient arm 53 projects into the recess 92. In this manner, the needle shroud 5 and actuation collar 9 are axially coupled such that axial movement of the needle shroud 5 induces axial movement of the actuation collar 9.
[0234] At the bottom of FIG. 67, it can be seen that the recess 92 is L-shaped and includes two sections adjacent to each other in an angular direction. In the locked state shown in FIG. 67, the resilient arm 53 engages with the first section of the recess 92. The first section of the recess 92 is bounded by edges of the actuation collar 9 in the proximal direction P and the distal direction D. Thus, axial movements of the needle shroud 5 in the proximal direction P and the distal direction D cause the protrusion of the resilient arm 53 to hit one of these edges. As a result, when the needle shroud 5 is moved in the distal direction D, the actuation collar 9 is moved in the distal direction D, and when the needle shroud 5 is moved in the proximal direction P, the actuation collar 9 is moved in the proximal direction P. In other words, the needle shroud 5 is coupled to the actuation collar 9 in the proximal direction P and the distal direction D.
[0235] On the other hand, the second section of the recess 92 is bounded only in the proximal direction P by an edge of the actuation collar 9. The second section of the recess 92 is open in the distal direction D and is not bounded by an edge of the actuation collar 9. Thus, if the protrusion of the resilient arm 53 engages the second section of the recess 92, moving the needle shroud 5 in the proximal direction P will cause the protrusion to hit an edge of the actuation collar 9, which will also move in the proximal direction P. However, moving the needle shroud 5 in the distal direction D will cause the resilient arm 53 and the recess 92 to disengage.
[0236] Further, in FIG. 67 it can be seen that the actuation collar 9 is coupled to the drive spring holder 4 via a first rotation lock interface. The first rotation lock interface prevents the rotation of the actuation collar 9 relative to the drive spring holder 4. On the other hand, as can be seen in FIG. 70 the rotation collar 2 and the actuation collar 9 are coupled via a second rotation lock interface. The second rotation lock interface prevents the rotation of the rotation collar 2 relative to the actuation collar 9. Thus, in summary, the rotation of the rotation collar 2 relative to the drive spring holder 4 is prevented by two rotation lock interfaces.
[0237] The first rotation locking interface is established by a slit 91a in the actuation collar 9 and a rib 47 of the drive spring holder 4 that engages in the slit 91. The rib 47 and the slit 91 are each elongated and have a main extension direction along the longitudinal axis. As can be seen in FIG. 67, the slit 91a is a first section of a recess 91 in the actuation collar 9. The recess 91 also includes a second section 91b adjacent to the slit 91a in the distal direction D. Measured along the angular direction, the slit 91 has a smaller width than the second section 91b. The width of the second section 91b first increases in the direction away from the slit 91a and then becomes constant. Within this region of increasing width, the second section 91b is delimited by a slope 91c of the actuation collar 9 that is inclined with respect to the longitudinal axis and the direction of rotation. This slope 91c provides a sliding function. In the locked state shown in FIG. 67, the rib 47 engages in the slit 91a of the recess 91.
[0238] As can be seen in Fig. 70, the second rotation lock interface is achieved by the projection 93 of the actuation collar 9 and the projection 24 of the rotatable collar 2 abutting one another in an angular direction. The projection 93 of the actuation collar 9 projects radially inward and the projection 24 of the rotatable collar 2 projects radially outward. The projections 24, 93 abut one another such that rotation of the rotatable collar 2 relative to the actuation collar 9 induced by the biased torsional drive spring 3 is prevented or blocked by the actuation collar 9.
[0239] FIG. 68 shows the auto-injector 1000 in a position where the needle shroud 5 has been moved proximally from its extended position towards the retracted position. The needle shroud 5 is now in an intermediate position between the extended and retracted positions. In this intermediate position, the rib 47 is transferred from the slit into the second section 91b. The force induced by the drive spring 3 presses the ramp 91c against the rib 47, which slides along the ramp 91c, thereby rotating the activation collar 9 by a predetermined angle in a first rotational direction relative to the drive spring holder 4 and the needle shroud 5. This rotation occurs automatically, since the torque induced by the torsion drive spring 3 is transferred via the rotation collar 2 to the activation collar 9 (via the second rotation lock interface). After the predetermined angle of rotation, the edge of the activation collar 9, which extends parallel to the longitudinal axis and defines the second section 91b of the recess 91 in the angular direction, hits the rib 47. At this time, further rotation of the actuation collar 9 relative to the drive spring holder 4 in the first rotational direction is prevented.
[0240] However, as a result of the actuation collar 9 rotating a predetermined angle in the first rotational direction, the resilient arm 53 of the needle shroud 5 then engages the second section of the recess 92 of the actuation collar 9, thereby decoupling the actuation collar 9 and the needle shroud 5 in the distal direction D. In other words, the coupling of the needle shroud 5 and the actuation collar 9 in the distal direction D is released.
[0241] FIG. 69 shows the automatic injector 1000 in a position in which the needle shroud 5 is further moved in the proximal direction P to a retracted position, and the activation collar 9 is also further moved in the proximal direction P. In this retracted position of the needle shroud 5, the needle 80 of the automatic injector 1000 can be exposed, thereby allowing the needle 80 to be penetrated into the body tissue. In the retracted position of the needle shroud 5, the second rotation lock interface between the activation collar 9 and the rotation collar 2 is released, i.e. the protrusions 24 and 93 are now axially offset and no longer abut each other, and thus the automatic injector 1000 is in a released state, in which rotation of the rotation collar 2 relative to the activation collar 9 and the drive spring holder 4 is enabled. The rotation collar 2 rotates in a first rotational direction, thereby driving the plunger rod 1 in the distal direction D, so that the drug is delivered through the needle 80 (see above description).
[0242] Further movement of the actuation collar 9 in the proximal direction P results in a second interlocking feature 90, i.e. clip 90, of the actuation collar 9 engaging with the interlocking feature 48, i.e. recess 48, of the drive spring holder 4. The engagement between the clip 90 and the recess 48 is such that movement of the actuation collar 9 in the distal direction D is prevented. When the needle shroud 5 is moved from the retracted position back towards or into the extended position, the actuation collar 9 no longer complies and is unable to follow. As described above, movement of the needle shroud 5 in the distal direction D relative to the actuation collar 9 is enabled because the resilient arm 53 engages the second section of the recess 92.
[0243] Figures 71 to 73 show different positions during assembly of the auto-injector 1000 according to the third exemplary embodiment: The rear sub-assembly is fitted into the front sub-assembly.
[0244] Figure 71 shows a first position, in which the needle shroud 5 of the front sub-assembly and the activation collar 9 of the rear sub-assembly are not yet coupled to one another. Figure 71 is a side view of the auto-injector 1000 during assembly.
[0245] Figure 72 shows the position of figure 71 in a cross-sectional view. It can be seen that the elastic arm 53 of the needle shroud 5 has a sliding function in the form of a ramp. This ramp is designed in such a way that, when it hits the distal end of the actuation collar 9, a force is generated which presses the elastic arm 53 radially outwards. The rear and front subassemblies can then be fitted further into each other, and the projection of the elastic arm 53 slides into the recess 92 of the actuation collar 9 as soon as it overlaps this recess 92 axially and non-rotatably. In this way, a connection between the actuation collar 9 and the needle shroud 5 is obtained.
[0246] FIG. 73 shows the auto-injector after connection of the needle shroud 5 and activation collar 9.
[0247] Further Explanations and Definitions The terms "drug" or "medicament" are used interchangeably herein to describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or their pharma- ceutically acceptable salts or solvates, and optionally a pharma- ceutically acceptable carrier. An active pharmaceutical ingredient ("API"), in its broadest sense, is a chemical structure that has a biological effect on humans or animals. In pharmacology, drugs or medicines are used to treat, cure, prevent, or diagnose diseases or otherwise improve physical or mental well-being. Drugs or medicines can be used for a limited duration or periodically for chronic disorders.
[0248] As described below, drugs or agents may include at least one API or combinations thereof in various types of formulations for the treatment of one or more diseases. Examples of APIs may include small molecules with molecular weights of 500 Da or less, polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes), carbohydrates and polysaccharides, as well as nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.
[0249] The drug or agent can be contained in a primary package or "drug container" adapted for use in a drug delivery device. The drug container can be, for example, a cartridge, syringe, reservoir, or other rigid or flexible vessel configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more drugs. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber can be designed to store the drug for about one month to about two years. Storage can be at room temperature (e.g., about 20° C.) or at refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some cases, the drug container can be or include a dual-chamber cartridge configured to separately store two or more components of a pharmaceutical formulation to be administered (e.g., an API and a diluent, or two different drugs), one in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between two or more components prior to and / or during administration to the human or animal body. For example, the two chambers can be configured to be in fluid communication with each other (e.g., via a conduit between the two chambers) and to allow mixing of the two components by a user, if desired, prior to administration. Alternatively or additionally, the two chambers can be configured to allow mixing upon administration of the components to the human or animal body.
[0250] The drugs or agents contained in the drug delivery devices described herein can be used for the treatment and / or prevention of many different types of medical disorders. Examples of disorders include, for example, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolic disorders, such as deep vein thromboembolism or pulmonary thromboembolism. Further examples of disorders are acute coronary syndromes (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs are those found in handbooks such as Rote Liste 2014 (e.g., but not limited to, main groups 12 (antidiabetic agents) or 86 (oncology agents)) and the Merck Index, 15th edition.
[0251] Examples of APIs for the treatment and / or prevention of type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma-ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analog" and "derivative" refer to a polypeptide having a molecular structure that is formally derivable from the structure of a naturally occurring peptide, e.g., the structure of human insulin, by deletion and / or replacement of at least one amino acid residue present in the naturally occurring peptide and / or by addition of at least one amino acid residue. The added and / or replaced amino acid residue can be either a codable amino acid residue or another naturally occurring residue or a purely synthetic amino acid residue. Insulin analogs are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide having a molecular structure formally derivable from the structure of a naturally occurring peptide, e.g., the molecular structure of human insulin in which one or more organic substituents (e.g., fatty acids) are attached to one or more of the amino acids. Optionally, one or more amino acids present in the naturally occurring peptide are deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable ones, are added to the naturally occurring peptide.
[0252] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline in position B28 may be replaced by Asp, Lys, Leu, Val or Ala and in which the Lys in position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
[0253] Examples of insulin derivatives are e.g. B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl-LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin. ; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
[0254] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists are, for example, lixisenatide (Lyxumia®), exenatide (exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide produced by the salivary glands of the flathead monster), liraglutide (Victoza®), semaglutide, taspoglutide, albiglutide (Syncria®), dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, langrenatide / HM-11260C (efpegrenatide). , HM-15211, CM-3, GLP-1 Erigen, ORMD-0901, NN-9423, NN-9709, NN-9924, NN-9926, NN-9927, Nodexene, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, ZP -DI-70, TT-401 (Pegapamodtide), BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Tirzepatide (LY3298176), Bamadutide (SAR425899), Exenatide-XTEN and Glucagon-Xten.
[0255] Examples of oligonucleotides are, for example, the cholesterol-lowering antisense therapeutic mipomersen sodium (Kynamro®) for the treatment of familial hypercholesterolemia, or RG012 for the treatment of Alport Syndrome.
[0256] Examples of DPP4 inhibitors are linagliptin, vidagliptin, sitagliptin, denagliptin, saxagliptin, berberine.
[0257] Examples of hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropine (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.
[0258] Examples of polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin or very low molecular weight heparin or derivatives thereof, or sulfated polysaccharides, such as the above-mentioned polysaccharides in polysulfated form, and / or their pharma- ceutically acceptable salts. An example of a pharma-ceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F20 (Synvisc®), sodium hyaluronate.
[0259] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind to an antigen. An antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., murine) antibody, or a single chain antibody. In some embodiments, an antibody has effector function and is capable of fixing complement. In some embodiments, an antibody has reduced or no binding ability to Fc receptors. For example, an antibody can be an isotype or subtype, an antibody fragment, or a mutant that does not support binding to Fc receptors, e.g., with a mutation or deletion of the Fc receptor binding region. The term antibody also includes antigen-binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or dual variable region antibody-like binding proteins (CODV) with crossover binding region orientation.
[0260] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., antibody heavy and / or light chain polypeptide) derived from an antibody polypeptide molecule that does not include the full-length antibody polypeptide but comprises at least a portion of the full-length antibody polypeptide that is still capable of binding to an antigen. An antibody fragment can include truncated portions of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments, such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments, such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
[0261] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences in the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences in the variable regions of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the proper arrangement of the CDR sequences to allow antigen binding. Although the framework region itself typically does not directly participate in antigen binding, as is known in the art, certain residues in the framework region of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with the antigen.
[0262] Exemplary antibodies are anti-PCSK-9 mAb (eg, alirocumab), anti-IL-6 mAb (eg, sarilumab), and anti-IL-4 mAb (eg, dupilumab).
[0263] Pharmaceutically acceptable salts of any of the APIs described herein are contemplated for use in the drug or medicament in the drug delivery device. Pharmaceutically acceptable salts include, for example, acid addition salts and base salts.
[0264] Those skilled in the art will understand that modifications (additions and / or deletions) can be made to the various components of the APIs, formulations, apparatus, methods, systems, and embodiments described herein without departing from the full scope and spirit of the present invention, and the present invention encompasses such modifications and all equivalents thereof. An exemplary drug delivery device can include a needle-based injection system as described in Table 1 of Chapter 5.2 of ISO11608-1:2014(E). As described in ISO11608-1:2014(E), needle-based injection systems can be broadly distinguished into multi-dose container systems and single-dose (partial or full discharge) container systems. The container can be an exchangeable container or an integrated non-exchangeable container.
[0265] As further described in ISO11608-1:2014(E), a multi-dose container system can include a needle-based injection device with an exchangeable container. In such a system, each container holds multiple doses and the dose size can be fixed or variable (pre-set by the user). Another multi-dose container system can include a needle-based injection device with an integrated non-exchangeable container. In such a system, each container holds multiple doses and the dose size can be fixed or variable (pre-set by the user).
[0266] As further described in ISO11608-1:2014(E), the single-dose container system can include a needle-based injection device with a replaceable container. In one example of such a system, each container holds a single dose, and thus the entire deliverable volume is expelled (full expelled). In a further example, each container holds a single dose, and thus a portion of the deliverable volume is expelled (partial expelled). As also described in ISO11608-1:2014(E), the single-dose container system can include a needle-based injection device with an integrated non-replaceable container. In one example of such a system, each container holds a single dose, and thus the entire deliverable volume is expelled (full expelled). In a further example, each container holds a single dose, and thus a portion of the deliverable volume is expelled (partial expelled).
[0267] The invention described herein is not limited by the description in relation to the exemplary embodiments, but rather includes any novel configuration and any combination of configurations, and in particular any combination of configurations in the claims, even if such configuration or such combination is not itself explicitly recited in the claims or in the exemplary embodiments. [Explanation of symbols]
[0268] 1 Plunger Rod 2 Rotating Color 3 Torsion drive spring 4 Drive spring holder 4a first section of drive spring holder 4 4b second section of drive spring holder 4 4c First bottom ring of drive spring holder 4 4d second bottom ring of drive spring holder 4 5 Needle Shroud 5a Cylindrical part 5b Arm 6 Drug Container Holder / Syringe Holder 6a Cylindrical section 6b Arm 6c Support part 7 Shroud spring 8 Drug containers / syringes 9 Startup Color 10 grooves 11 External Thread 12 Piston 13 Displaceable Arm 14 Feedback energy member / spring 20 Axis 21 First Part 22 Second Part 22a surface 23 Recess 24 protrusions 40 protrusions 40a: Edge portion within drive spring holder 4 41 Elastic Arm 43 Recess 44 Recess 45 Protrusion 46 Flap 47 Ribs 48 Recess 50a wall section 50b Recess 51 Elastic Arm 51a ramp 52 Recess 53 Elastic Arm 54 Recess 60 Windows 60a wall section 61 Rib 62 Snap function 63 Pressing element 64 Release element 80 needles 81 Cartridge 82 Stopper 83 Needle Shield 90 clips 91 Recess 91a Slit / first section of recess 91 91b Second section of recess 91 91c slope 92 Recess 93 Protrusion 100 Housing 101 Protrusion 102 Rear Cap 110 Cap 110a Elastic Arm 110b protrusion 111 Gripping part 120 Window 130 Protrusion 200 hollow 201 Impact Function 210 Elastic Arm / Clip 220 Recess 220b First section of recess 220 220c Second section of recess 220 220d Surface of the recess 220 221 Recess 221a Slope 410 Protrusion 410a Slope 410b First section of protrusion 410 410c second section of protrusion 410 410d Surface of protrusion 410 411 Protrusion 411a Slope 1000 Drug Delivery Devices / Auto-Injectors FSA Forward Subassembly RSA Rear Subassembly α angle D Distal direction P Proximal direction A Longitudinal / Axial R Radial direction C Orientation / Rotation / Angle Direction
Claims
1. A drug delivery device (1000), comprising: A housing element (4), a protective member (5) arranged axially movably relative to the housing element (4) and configured to cover the drug delivery element (80); a movable member (2) arranged to be movable relative to a housing element (4); a first stop feature (51) axially fixed relative to the protective member (5); and a second stop feature (22a, 40a) configured to interact with said first stop feature (51), wherein: The drug delivery device is configured to perform a drug delivery operation; The drug delivery device (1000) is configured to be switchable from an initial state to a released state, and in the released state: The protective member (5) is in a proximal position; The movable member (2) moves to a locking position, The drug delivery device (1000) is configured to be switchable from a released state to a post-released state by moving the protective member (5) from a proximal position in a distal direction (D) to a post-released position, and in the post-released state: The protective member (5) is in a post-release position; The drug delivery device, wherein the movable member (2) is in a locking position and an interaction between the first stop feature (51) and the second stop feature (22a, 40a) is effective, such that when an attempt is made to move the protective member (5) in the proximal direction (P), the stop features (51, 22a, 40a) interact with each other before the protective member (5) reaches a proximal position, said interaction preventing further movement of the protective member (5) in the proximal direction (P).
2. The movable member (2) is arranged to be axially movable relative to the housing element (4); In the released state, the movable member (2) moves axially to a locking position. The drug delivery device (1000) of claim 1.
3. The movable member (2) is rotatably arranged relative to the housing element (4), In the released state, the movable member (2) rotates. A drug delivery device (1000) according to claim 1 or 2.
4. A drug delivery device (1000), comprising: A housing element (4), a protective member (5) arranged axially movably relative to the housing element (4) and configured to cover the drug delivery element (80); a movable member (2) arranged to be movable relative to a housing element (4); a first stop feature (51) axially fixed relative to the protective member (5); and a second stop feature (22a, 40a) configured to interact with said first stop feature (51), wherein: The drug delivery device is configured to perform a drug delivery operation; The drug delivery device (1000) is configured to be switchable from an initial state to a released state, and in the released state: The protective member (5) is in a proximal position; The movable member (2) moves to a locking position, The drug delivery device (1000) is configured to be switchable from a released state to a post-released state by moving the protective member (5) from a proximal position in a distal direction (D) to a post-released position, and in the post-released state: The protective member (5) is in a post-release position; the movable member (2) is in a locking position, the interaction of the first stop feature (51) and the second stop feature (22a, 40a) is effective, such that when an attempt is made to move the protective member (5) in the proximal direction (P), the stop features (51, 22a, 40a) interact with each other before the protective member (5) reaches the proximal position, said interaction preventing further movement of the protective member (5) in the proximal direction (P); Said drug delivery device, wherein in a released state the movable member (2) moves axially in a proximal direction and / or rotates.
5. In the initial state, the protective member (5) is in a pre-release position and is distally offset relative to a proximal position; A drug delivery device (1000) as described in any one of claims 1 to 4, wherein the movable member (2) is in an unlocked position, and the interaction of the first stop feature (51) and the second stop feature (22a, 40a) is disabled, thus making it possible to move the protective member (5) in the proximal direction (P) from the pre-release position to the proximal position.
6. The drug delivery device (1000) is configured to be switchable from an initial state to a released state by moving the protective member (5) from a pre-release position to a proximal position. The drug delivery device (1000) of claim 5.
7. a plunger rod (1) arranged axially movable relative to a housing element (4); and an energy member (3) for providing energy to induce axial movement of the plunger rod (1) in the distal direction (D), In the released state, The plunger rod (1) is moved in a distal direction (D) by the energy provided by the energy member (3), The movable member (2) is moved by energy provided by an energy member (3). A drug delivery device (1000) according to any one of claims 1 to 6.
8. the movable member (2) and the plunger rod (1) are operatively coupled such that movement of the movable member (2) in a first direction is translated into movement of the plunger rod (1) in a distal direction (D); In the released state, The energy member (3) induces a force on the movable member (2) causing the movable member (2) to move in a first direction, thereby axially moving the plunger rod (1) in a distal direction (D); The drug delivery device (1000) of claim 7.
9. The second stop feature (22a) is axially and non-rotatably fixed to the movable member (2); A drug delivery device (1000) according to any one of the preceding claims.
10. The second stop feature (22a) extends completely circumferentially around the axis of rotation of the movable member (2); A drug delivery device (1000) according to at least claim 8 and claim 3 or 4.
11. In an initial state, the second stop feature (22a) is disposed distally relative to the first stop feature (51); In a released state, the second stop feature (22a) is disposed proximally relative to the first stop feature (51). A drug delivery device (1000) according to claim 9 or 10.
12. The drug delivery device (1000) according to any one of the preceding claims, wherein the second stop feature (40a) is axially fixed relative to the housing element (4).
13. one of the first stop feature (51) and the second stop feature (22a, 40a) is a displaceable feature that is radially displaceable; the stop features (51, 22a, 40a) are configured to pass each other without interaction when the displaceable stop feature (51) is in a first radial position, and to interact with each other when the displaceable stop feature (51) is in a second radial position; A drug delivery device (1000) according to any one of the preceding claims.
14. the movable member (2) in the unlocked position is configured to hold the displaceable stop feature (51) in a first radial position before the first stop feature (51) reaches the second stop feature (40a) when the protective member (5) is moved in the proximal direction (P); A drug delivery device (1000) according to at least one of claims 5 and 13.
15. When the first fastening feature (51) and the second fastening feature (22a, 40a) interact with each other, a locking interface is formed between the first fastening feature (51) and the second fastening feature (22a, 40a); the locking interface is configured to prevent the displaceable stop feature (51) from being displaced to the first radial position; A drug delivery device (1000) according to claim 13 or 14.
16. a housing (100) having a housing element (4) fixed or integrated within the housing (100); a drug container (8) having a needle (80); The protective member (5) is matingly connected to the housing (100); In the released position, the needle (80) is covered by a protective member (5); In the proximal position, the needle (80) is exposed. A drug delivery device (1000) according to any one of the preceding claims.
17. The drug delivery device (1000) of claim 16, wherein the drug container (8) contains a drug or medication.
18. The drug delivery device (1000) according to any one of claims 1 to 17, wherein the protective member (5) is a needle shroud (5).
19. The drug delivery device (1000) of any one of claims 1 to 18, wherein the second stop feature includes a recess or notch, and when the first stop feature and the second stop feature interact with each other, the first stop feature protrudes or engages into this recess or notch.
20. A drug delivery device (1000), comprising: A housing element (4), a protective member (5) arranged axially movably relative to the housing element (4) and configured to cover the drug delivery element (80); a movable member (2) arranged to be movable relative to a housing element (4); a first stop feature (51) axially fixed relative to the protective member (5); and a second stop feature (22a, 40a) configured to interact with said first stop feature (51), wherein: The drug delivery device is configured to perform a drug delivery operation; The drug delivery device (1000) is configured to be switchable from an initial state to a released state, and in the released state: The protective member (5) is in a proximal position; The movable member (2) moves to a locking position, The drug delivery device (1000) is configured to be switchable from a released state to a post-released state by moving the protective member (5) from a proximal position in a distal direction (D) to a post-released position, and in the post-released state: The protective member (5) is in a post-release position; the movable member (2) is in a locking position, the interaction of the first stop feature (51) and the second stop feature (22a, 40a) is effective, such that when an attempt is made to move the protective member (5) in the proximal direction (P), the stop features (51, 22a, 40a) interact with each other before the protective member (5) reaches the proximal position, said interaction preventing further movement of the protective member (5) in the proximal direction (P); The drug delivery device, wherein in a released state, the movable member moves axially in a proximal direction and rotates.
